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Summary 
SUMMARY 
The CD95 (APO-1/Fas)-mediated apoptotic pathway is one of the well-studied death 
receptor pathways. CD95 is a highly glycosylated type I transmembrane protein and 
has a molecular mass of 37.5 kDa. The N-terminal domain of CD95 contains two 
putative N-linked glycosylation sites at N118 and N136 and posttranslational 
glycosylation leads to an increase of molecular mass of CD95 to 45–52 kDa. Upon 
stimulation of CD95, either with its natural ligand CD95L or with agonistic antibodies 
such as anti-APO-1, a Death-Inducing Signaling Complex (DISC) is formed. The 
DISC consists of oligomerized, most probably trimerized, CD95, the DD-containing 
adaptor molecule Fas associated death domain containing protein (FADD), 
procaspase-8, procaspase-10 and cellular FLICE inhibitory protein  (c-FLIP). The 
interactions between the molecules in the DISC are based on homophilic contacts. 
The death domain (DD) of CD95 interacts with the DD of FADD while the death 
effector domain (DED) of FADD interacts with the N-terminal tandem DED of 
procaspase-8. Binding of procaspase-8 to the DISC results in its autocatalytic 
cleavage with the formation of the mature caspase-8 which is released into the 
cytosol to propagate the apoptotic signal.  
The data presented here show that N-glycosylation of CD95 influences death-
inducing signaling complex (DISC) formation and procaspase-8 activation at the 
CD95 DISC. Treatment with the chemical inhibitors of N-glycosylation tunicamycin 
and Deoxymannojirimycin (DMM), neuraminidase from Vibrio cholerae and 
generation of CD95 glycosylation mutants at N136 and N118 show that 
N-deglycosylation of CD95 results in the reduction of caspase-8 processing at the 
DISC. Modelling of the core CD95 DISC structure and the structure of the CD95 
DISC network on the membrane indicated that the glycan attached to N118 could be 
important for the contacts between neighboring DISCs forming a network. A glycan 
moiety attached to N136 of CD95 could be important for the complex formation 
and/or stability as it is located in close proximity to one of the CD95L molecules. 
The present study shows that the CD95 glycostructure can contribute to the amount 
of generated caspase-8, which defines cell death initiation. This regulation might be 
important for cancer cells when a subtle difference in the amount of activated 
caspase-8 regulates life or death of the cell. 
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Summary 
ZUSAMMENFASSUNG 
Apoptose ausgelöst durch CD95 (APO-1/Fas) gehört zu den bestuntersuchtesten 
Signalwegen. CD95 ist ein hochglykosyliertes Typ I Transmembranprotein und hat 
eine molekulare Masse von ca. 37,5 kDa. Die N-terminale Domäne von CD95 enthält 
zwei mögliche stickstoffverbundene Glykosylierungsstellen an Position N118 und 
N136. Die posttranslationale Glykosylierung führt zu einer Erhöhung der molekularen 
Masse von CD95 auf 45–52 kDa. Nach Stimulierung von CD95 mit seinem 
natürlichen Liganden CD95L oder mit dem agonistischen Antikörper anti-APO-1, 
bildet sich der Death-Inducing Signaling Complex (DISC).  
Der DISC besteht aus oligomerisiertem, wahrscheinlich trimerisiertem CD95 und  
dem Adaptermolekül Fas associated death domain containing protein (FADD), 
Procaspase-8, Procaspase-10 und  cellular FLICE inhibitory protein  (c-FLIP). Alle 
Interaktionen am DISC basieren auf homophilen Proteinbindungen. Mittels seiner 
Todesdomäne wird FADD an CD95 rekrutiert und via  seiner Todeseffektordomänen 
kommt es zur Rekrutierung von Procaspase-8 an den DISC. Die Rekrutierung von 
Procaspase-8 an den DISC führt zur autokatalytischen Spaltung und Bildung der 
aktiven Caspase-8. Diese wird ins Zytosol freigesetzt und initiiert Apoptose.  
In dieser Arbeit konnte gezeigt werden, dass die CD95 N-Glykosylierung die 
Formierung des DISC und die damit verbundene Aktivierung der Procaspase-8 am 
CD95-DISC beeinflusst. Mittels Inhibitorstudien und der Herstellung von 
Glykosylierungsmutanten (N118Q and N136Q), sowie der Untersuchung von 
deglycosyliertem CD95 (durch Neuraminidase-Behandlung) konnte demonstriert 
werden, dass die N-Deglykosylierung von CD95 in einer verminderten Prozessierung 
von Procaspase-8 resultiert.  
Die Modellierung der CD95 DISC-Struktur und der Vernetzung mehrerer CD95-
DISCs an einer Membran hat gezeigt, dass das Glykan, welches an N118 angeheftet 
ist, für den Kontakt zwischen benachbarten DISCs eine Rolle spielen kann. Auch an 
N136 befestigte Glykanreste könnten wichtig für die Komplexbildung und/oder die 
Stabilität von CD95 sein, da sie in der direkten Umgebung der CD95L Moleküle liegt.  
Diese Untersuchungen demonstrieren, dass die Glykosylierung von CD95 Einfluss 
auf die Bildung aktiver Caspase-8 hat, welche die Initierung des Zelltods bestimmt. 
Dies kann Bedeutung für die Entstehung von Krebszellen haben, da geringe 
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Summary 
Mengenunterschiede an aktiver Caspase-8 Überleben oder Tod der Zelle 
beeinflussen. 
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Introduction 
1. INTRODUCTION 
1.1. Apoptosis 
1.1.1. Types of cell death  
Cell death is an essential and highly orchestrated process in multicellular 
organisms. It plays an important role during development, for homeostasis of tissue  
in mature organisms and for elimination of infectious pathogens (Krammer 2000; 
Strasser et al. 2009). Defective regulation of cell death leads to a spectrum of 
diseases such as diabetes, degenerative disorders and cancer.  
There are three major types of cell death: apoptosis, necrosis and autophagy 
which can be distinguished by morphology (Fig. 1). 
 
Figure 1. Morphological features of autophagic, apoptotic and necrotic cells. A. Viable 
cell. B. Autophagic cell. C. Apoptotic cell. D. Necrotic cell. (Edinger et al. 2004). 
Apoptosis - programmed cell death - is a highly regulated physiological process of 
cell death that is conserved among all multicellular organisms. The term is derived 
from ancient Greek (apo = off, ptosis = falling, dropping), meaning the ‘‘falling off of 
petals from a flower’’ or ‘‘of leaves from a tree in autumn’’. It was first introduced by 
John Kerr in 1972 and refers to the morphological feature of formation of “apoptotic 
bodies” from a cell during the course of apoptosis (Kerr et al. 1972). The 
phenomenon was discovered in 1842 by the German scientist Carl Christoph Vogt 
who showed that in the course of development of the midwife toad tadpole (Alytes 
obstetricians), cells undergo programmed cell death.  
Apoptotic cells are usually rounding up, retract pseudopodes, reduce cellular and 
nuclear volume and show nuclear fragmentation and plasma membrane blebbing 
(Fig. 1C). Usually, they are quickly engulfed by resident phagocytes (Kroemer et al. 
2009).  
Necrosis (from the Greek νεκρός, "dead") is the death  by injury of cells and living 
tissue (Syntichaki et al. 2003). Typically it is caused by external factors, such as 
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infection, toxins or trauma. It can be characterized by cytoplasmic swelling, rupture of 
the plasma membrane, swelling of cytoplasmic organelles and a moderate chromatin 
condensation (Fig. 1D). 
During autophagic cell death, the cell's own components are degraded by the 
lysosomal machinery (Kundu et al. 2008). Autophagy can be characterized by a lack 
of chromatin condensation, massive vacuolization of the cytoplasm and accumulation 
of autophagic vacuoles. Furthermore, autophagic cells are rarely taken up by 
phagocytic cells in vivo (Fig. 1B). 
 
1.1.3. Apoptosis in the immune system  
Apoptosis plays an essential role in the immune system during the development of 
lymphocytes and the regulation of the immune response. Aberrations in genes 
encoding pro- or anti-apoptotic proteins have been implicated in the initiation of 
diseases such as immunodeficiency, autoimmunity and cancer (Krammer 2000). 
 
Figure 2. The course of a T cell immune response and Activation-Induced Cell Death 
(AICD). A. The T cell immune response comprises a clonal expansion and effector phase, a 
“down” or “retraction” phase, and a memory phase. During the clonal expansion and effector 
phase, proliferating T cells are resistant to apoptosis. In the down phase T cells become 
sensitive to apoptosis. By contrast, in the memory phase T cells become again resistant to 
apoptosis. B. The CD95/CD95L system plays an important role in AICD. Naive T cells do not 
express CD95L. Upon TCR triggering T cells start to express CD95L and become sensitive 
to CD95-mediated apoptosis. Adapted from Krammer 2000. 
The survival of lymphocytes is regulated at several points in their lifespan 
(Strasser 1995). During lymphocyte development, survival depends on signaling 
through their antigen receptors. The selection is highly stringent, resulting in the 
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elimination of most lymphocytes. Early survival of B or T cells requires a functional B 
cell - (BCR) or T cell receptor (TCR), respectively (Krammer 2000). Cells whose 
receptors do not recognize antigen are eliminated by apoptosis. Lymphocytes 
expressing functional antigen receptors are then tested to determine whether they 
are autoreactive and dangerous. Antigen receptors that react strongly with a self-
antigen undergo cell death during negative selection (Krammer 2000). In contrast, 
cells that express functional receptors which do not react strongly with self-antigen 
differentiate into mature lymphocytes.  
Apoptosis also plays an important role during the regulation of T cell immune 
responses via Activation-Induced Cell Death (AICD) (Fig. 2). Typically, the immune 
response consists of several steps: in the clonal expansion/effector phase of the 
immune response, T cells are activated upon antigen recognition, proliferate and 
differentiate into effector cells. In this phase, they are resistant towards apoptosis. In 
the down phase of the immune response, T cells become sensitive to apoptosis and 
die by AICD. Memory T cells are resistant towards apoptosis and survive. The 
CD95/CD95L system plays an important role in AICD. Naive T cells do not express 
CD95L. Upon TCR triggering T cells start to produce CD95L and become sensitive to 
CD95-mediated apoptosis (Fig. 2B) (Krammer 2000). This was strongly supported by 
the phenotype of lpr and gld (CD95 and CD95L mutant) mice, which suffer from 
lymphoproliferation and autoimmunity due to lack of AICD (Martin et al. 1999). 
Mutations in the CD95/CD95L system are also responsible for most cases of the 
human autoimmune lymphoproliferative syndrome (ALPS) (Rieux-Laucat et al. 1995; 
Siegel et al. 2000). 
 
1.1.4. Apoptosis-associated disorders 
The diseases caused by a dysfunctional apoptotic cellular machinery can be 
divided into two groups characterized by "too little" apoptosis and "too much" 
apoptosis (Thompson 1995).  
The first group comprises neoplastic and autoimmune diseases associated with 
severe apoptosis inhibition (Kim et al. 2006; de Bruin et al. 2008). These diseases 
are distinguished by an excessive accumulation of cells such as cancer or 
autoimmune diseases. Neoplastic diseases are characterized by mutations in the cell 
cycle-regulating genes p53, ras or c-myc. Deregulation of genes leads to malignant 
degeneration and blockade of multiple apoptotic pathways (Chamond et al. 1999). 
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Deregulation of apoptotic pathways contributes to almost all stages of tumor 
development (Hanahan et al. 2000). Autoimmune diseases, such as systemic lupus 
erythematosus, may be associated with mutations in genes rendering the 
lymphocytes resistant to apoptosis (Thompson 1995).  
The second group of diseases is associated with "too much" apoptosis. A large 
group of neurodegenerative diseases, among them Alzheimer's disease, Parkinson's 
disease, amyotrophic lateral sclerosis and retinitis pigmentosa, are associated with 
increased susceptibility to apoptosis of neurons (Gschwind et al. 1995; Walkinshaw 
et al. 1995). 
During ischemia, e.g. myocardial infarction, ischemic renal damage or 
cerebrovascular accidents cell death is generally considered to occur through 
necrosis. However, cells surrounding the ischemic zone die through apoptosis 
(Vexler et al. 1997; Zhang et al. 2004; Hong et al. 2008). Apoptosis is thought to 
happen as a consequence of the alterations in the biochemical metabolism 
accompanying the ischemic process.  
The acquired immunodeficiency syndrome (AIDS), which is caused by infection 
with the human immunodeficiency virus (HIV), is characterized by an imbalance 
between the number of CD4+ lymphocytes and the ability of the bone marrow to 
generate new mature cells (Badley et al. 2000). The CD4+ cells of the patients die 
through apoptosis when stimulated in vitro. Apoptosis is supposed to be involved in 
the gradual CD4+ T cell depletion in the course of HIV infection (Ameisen 2001; 
Arthos et al. 2002; Herbeuval et al. 2005). 
 
1.1.5. Apoptotic signaling pathways 
A cell is responding to death signals by two major apoptotic pathways: the intrinsic 
pathway, which is triggered via mitochondria, and the extrinsic pathway, which is 
induced  by death receptor stimulation. 
 
1.1.5.1. The intrinsic mitochondrial pathway 
Apoptosis can be initiated by intrinsic signals that are produced in response to 
cellular stress (Fulda et al. 2006). Cellular stress can result from exposure to UV, γ-
irradiation, DNA damage and by TCR stimulation. It might also be a consequence of 
growth factor deprivation or oxidative stress caused by free radicals. These intrinsic 
signals initiate apoptosis via the mitochondria.  
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The regulation of the mitochondrial pathway is associated with the balance 
between proapoptotic and antiapoptotic members of the Bcl-2 family (Letai 2005). 
Intracellular stress is first sensored by the so called "BH3-only subfamily" proteins 
bearing only one of the BH3 domains, e.g. Bid, Bim, Harikari, Noxa, and Puma (Cory 
et al. 2002). These proapoptotic Bcl-2 family members transmit the stress signal via 
yet not completely known mechanisms to multidomain Bcl-2 family members: Bax, 
Bcl-xS, Nbk (also called Bik), Bak and Bad. This may lead to oligomerization of Bax 
and Bak and their insertion into the mitochondrial membrane. This association results 
in mitochondrial outer membrane permeabilisation (MOMP) and a breakdown of the 
mitochondrial membrane potential. Antiapoptotic members of the family such as 
Bcl-2, Bcl-xL, Bfl-1/A1 and Mcl-1 block apoptosis by preventing the mitochondrial 
release of the intermembrane proteins from mitochondria, including cytochrome c 
(Bouillet et al. 2002).  
After MOMP cytochrome c is released from the mitochondria into the cytoplasm 
(Green et al. 1998). Release of cytochrome c from mitochondria leads to association 
with Apaf-1 (apoptosis protease-activating factor 1) in an ATP-dependent way. Apaf-
1 is recruited and interacts via its CARD domain with the CARD domain of 
procaspase-9. These events lead to formation of a complex called apoptosome 
(Korsmeyer et al. 2000). The apoptosome consists of procaspase-9, Apaf-1 and 
cytochrome c molecules (Srinivasula et al. 1998).  
Formation of the apoptosome leads to the activation of procaspase-9 that belongs 
to the caspase (cysteinyl aspartate proteinases) family (Salvesen 2002). Caspases 
are key enzymes of apoptotic signal transduction. They are synthesized as 
proenzymes containing an N-terminal prodomain, as well as p20 and p10 domains 
that form the active enzyme. Active caspase is a tetramer of two p20/p10 
heterodimers containing two active sites (Lavrik et al. 2005). Because cleavage sites 
of the p10 and p20 subunits contain critical aspartate residues and, hence, potential 
caspase substrate sequences, other active caspases can clip the prodomain from 
inactive caspases (Salvesen 2002). According to the length of their prodomain and 
their function, caspases are classified into initiator and effector caspases (Zou et al. 
1999; Acehan et al. 2002). Initiator apoptotic caspases comprise procaspase-9, 
procaspase-8, procaspase-10, and procaspase-2. Effector caspases comprise 
caspase-3, -6 and -7.  Activation of initiator caspases leads to the activation of 
effector caspases and ultimately to apoptosis. Procaspase-9 is proteolytically 
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activated at the apoptosome, and subsequently cleaves and activates effector 
caspase-3, -6 and -7 (Rodriguez et al. 1999).  
Caspase activation can be blocked by inhibitor of apoptosis family (IAPs) members 
consisting of eight mammalian proteins, including XIAP, C-IAP1 and -2, and 
MLIAP/livin (Siegelin et al. 2005). The activity of IAPs can be modulated by 
Smac/Diablo (second mitochondria-derived activator of caspase/direct IAP binding 
protein with low isoelectric point) (Shiozaki et al. 2004) and a mitochondria-located 
serine protease Omi/HtrA2, which are released from mitochondria (Faccio et al. 
2000).  
 
1.1.5.2. The extrinsic pathway 
The extrinsic apoptotic pathway is initiated by the binding of death-inducing ligands 
to cell surface receptors called death receptors (DR) (Wajant 2003). The detailed 
structure and function of DRs as well as the signal transduction of the extrinsic 
apoptotic pathway is described in the next chapter. 
 
1.2. Death receptors 
The DR family (Fig. 3) is a subfamily of the tumor necrosis factor receptor (TNFR) 
superfamily which includes tumor necrosis factor receptor 1 (TNFR1), also known as 
DR1, CD120a, p55 and p60; CD95 also known as Fas, APO-1 and DR2; DR3 also 
known as APO-3, LARD, TRAMP and WSL1; TNF-related apoptosis-inducing ligand 
receptor 1 (TRAILR1), also known as DR4 and APO-2; TRAILR2 also known as DR5, 
KILLER and TRICK2; DR6 (TNFRSF21), ectodysplasin A receptor (EDAR) and nerve 
growth factor receptor (NGFR) (French et al. 2003; Wajant 2003). All members of the 
DR subfamily have a cytoplasmic region of about 80 residues called death domain 
(DD), which plays an important role in signal transduction. DRs can activate apoptotic 
and non-apoptotic pathways via formation of the corresponding receptor complexes 
(Fig. 3). 
Two types of DR signaling complexes are known so far. The first group comprises 
the death-inducing signaling complexes (DISCs) that are formed by CD95, TRAILR1 
or TRAILR2 (Peter et al. 1999; Lavrik et al. 2005) (Fig. 3). 
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All three receptors form DISCs with a similar composition. DISC formation results 
in the activation of procaspase-8, which plays a central role in the transduction of the 
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apoptotic signal (Fig. 3). The second group comprises the TNFR1, DR3, DR6 and 
EDAR. These recruit a different set of molecules that could transduce both apoptotic 
and survival signals. 
Death ligands also interact with decoy receptors (DcRs) that do not possess DDs 
and therefore can not form signaling complexes. To date, four decoy receptors have 
been characterized: TRAILR3 also known as DcR1, TRAILR4 also known as DcR2, 
DcR3 and osteoprotegrin (OPG) (Lavrik et al. 2005).  
  
1.2.1. Signal transduction by death receptors 
1.2.1.1. CD95/Fas/APO-1 signaling 
The CD95-mediated apoptotic pathway is one of the most-studied DR pathways. 
The human CD95 is constitutively expressed in a wide range of hematopoetic and 
nonhematopoetic cells, and with particular abundance in thymus, liver and kidney 
(Leithauser et al. 1993).  
The human CD95 gene is a single copy gene comprising nine exons and eight 
introns (Behrmann et al. 1994). The promoter sequence contains consensus binding 
sites for transcription factors Sp1, AP-1, AP-2, Ets, GF-1, EBP20, c-myb, CREB, 
GAF, NF-κB, NF-AT, NY-Y and NF-IL6 (Cheng et al. 1995). Regulation of CD95 
expression has been described for a wide range of stimuli (Kontny et al. 2005). 
The classical view of DR function is typified by CD95 (Fas/APO-1) (Oehm et al. 
1992; Peter et al. 1998; Lavrik et al. 2005). Interactions of CD95 with its ligand, 
CD95L (CD178/FasL/TNSF6), play a pivotal role in the regulation of peripheral 
tolerance and lymphoid homeostasis. Natural mutations within CD95 and CD95L in 
humans and mice are associated with the development of autoimmune 
lymphoproliferative syndromes (Nagata 1999).  
 
1.2.1.1.1. CD95 DISC  
CD95 is expressed on the surface of cells possibly as preassociated homotrimers. 
Upon CD95L binding, CD95 likely undergoes a conformational change to reveal its 
cytoplasmic death domain (DD) to favor homotypic interactions with other DD 
containing proteins (Itoh et al. 1993; Boldin et al. 1995; Chinnaiyan et al. 1995). 
Binding of CD95L within seconds results in formation of the death-inducing signaling 
complex (DISC) (Peter et al. 2003) (Fig. 4). DISC formation starts with recruitment of 
the CD95-adaptor protein FADD (Fas-associated DD) t
Olga Shatnyeva 
 
24 
Introduction 
N-terminal part of FADD contains a death effector domain (DED) that recruits 
procaspase-8/10 or its enzymatically inactive homolog c-FLIPL/S/R (Fig. 4).  
 
Figure 4. Formation of CD95 DISC upon CD95L stimulation. The DISC consists of CD95, 
(depicted in yellow), FAS-associated death domain, FADD, (depicted in light blue), 
procaspase-8/procaspase-10, (depicted in green), and cellular FLICE-inhibitory proteins, 
c-FLIP,
 
(depicted in purple). The interactions between the molecules at the DISC are based 
on homotypic contacts. The death domain (DD) of CD95 interacts with the DD of FADD while 
the death effector domain (DED) of FADD interacts with the N-terminal tandem DEDs of 
procaspase-8, procaspase-10 and c-FLIP. DD are shown in red; DED are shown in light 
yellow. 
It has also been reported that RIP (Stanger et al. 1995), FAF1 (Chu et al. 1995), 
UBC-FAP (UBC9) (Wright et al. 1996), FAP-1 (Sato et al. 1995), Sentrin (Okura et al. 
1996), FLASH (Imai et al. 1999), Ezrin (Parlato et al. 2000), Btk (Jackson et al. 
1999), TRAF-1/2 (Kataoka et al. 2000) and Raf-1 are recruited to the DISC. The role 
of these proteins in the modulation of apoptotic signaling is still illusive. 
 
1.2.1.1.2. Proteins associated with the CD95 DISC 
1.2.1.1.2.1. FADD  
FADD is an essential protein for CD95 signaling, which acts by recruiting 
apoptosis-initiating procaspases-8 and -10 to the DISC. FADD has no enzymatic 
activity and consists of an N-terminal DD and a C-terminal DED (Fig. 5). FADD-
deficient MEFs and Jurkat T cells are completely resistant to apoptosis mediated by 
anti-CD95 agonistic antibodies, CD95L, TNFα, or TRAIL.  
Apart from its apoptotic function, it has been shown that FADD is crucially involved 
in development. FADD-deficient embryos die of heart defects at day 10 of gestation 
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(Varfolomeev et al. 1998; Yeh et al. 1998). It also appears to play a role in T and B 
lymphocyte development (Kabra et al. 2001; Zhang et al. 2001).  
 
 
Figure 5. DED-proteins of the DISC: c-FLIPL/S/R, procaspase-8, procaspase-10 and 
FADD. c-FLIP isoforms contain two death effector domains (DEDs) (depicted in grey). 
c-FLIPL contains caspase-like domains p20 and p12 (depicted in purple and brown). 
Aspartate residues which are needed proteolytic cleavage are shown with black arrows 
(D198, D376). Procaspase-8/10 contains two DEDs (depicted in grey), the large catalytic 
subunit p18/p20, respectively, (depicted in red) and the small catalytic subunit p10 (depicted 
in bordeux). Aspartate residues which are needed for caspase-8 proteolytic cleavage 
activation are shown with black arrows (D374, D384, D210 and D216). FADD contains a 
C-terminal DD (depicted in red) and an N-terminal DED (depicted in grey). Phosphorylation 
sites of FADD and procaspase-8 are shown with black arrows. 
 
Mice lacking FADD or expressing a dominant-negative FADD show reduced 
thymic cellularity and inhibition of T cell development. These mice also have defects 
in T cell receptor (TCR) activation-induced proliferation of T cells due to impaired 
G1→S transition (Walsh et al. 1998). FADD was shown to be selectively 
phosphorylated at Ser194 (Scaffidi et al. 2000). Highly phosphorylated FADD was 
found in cells in G2/M, whereas FADD phosphorylation was low in G1. The ability of 
FADD to promote cell cycle progression of T cells was found to depend on the 
phosphorylation of this site (Hua et al. 2003). 
 
1.2.1.1.2.2. Procaspase-8 
Caspase-8 has been identified as enzymatically active component of the CD95 
DISC (Kischkel et al. 1995). It was initially named CAP4 and later it got several other 
names such as FLICE (FADD-like Interleukin-1ß-converting enzyme), MACH (Boldin 
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et al. 1996) and MCH5 (Fernandes-Alnemri et al. 1996). Caspase-8 has a preferred 
substrate specificity for I/L/V/E-X-D, where X is any amino acid (Lavrik et al. 2005).  
The human gene is located at the locus 2q33-34. The murine homologue has been 
found in the chromosomal region 1B-proximal C (Kischkel et al. 1998). Procaspase-8 
is expressed in a wide range of the cells. Procaspase-8 knockout mice are prenatally 
lethal. Mutant MEFs are resistant to receptor-mediated apoptosis (Varfolomeev et al. 
1998; Kang et al. 2004). 
Eleven forms of procaspase-8 were described at the mRNA level, but only 5 
isoforms have been characterized so far at the protein level - caspase-8a, 
caspase-8b, caspase-8i, caspase-8k and caspase-8l (Eckhart et al. 2001; Himeji et 
al. 2002). Both procaspase-8a and -8b play a key role in apoptotic signaling as 
initiator caspases of the extrinsic apoptotic pathway. In addition, procaspase-8a and 
-8b are implicated in migration, adhesion, NF-κB activation, proliferation and 
differentiation (Fulda 2009). Caspase-8l has been shown to play an inhibitory role 
because it lacks a catalytic domain (Himeji et al. 2002). Caspase-8l expression has 
been reported to be regulated by alternative splicing in leukemia and neuroblastoma 
(Mohr et al. 2005). 
Procaspase-8a/b is a 55/53 kDa protein of 496/479 amino acids. It contains two 
DEDs in its N-terminal prodomain and two C-terminal catalytic protease domains: 
p18 and p10 (Fig. 5). The DEDs function as a platform for protein-protein interactions 
(Kischkel et al. 1995). Upon proteolytic activation at the DISC, active caspase-8 is 
generated as a heterotetramer consisting of two large (p18) and two small subunits 
(p10) (Lavrik et al. 2003). Besides its proteolysis at the DISC, procaspase-8 can also 
be activated downstream of mitochondria upon initiation of the intrinsic apoptosis 
pathway, e.g. via caspase-6 (Fulda 2009).  
The mechanism of procaspase-8 activation at the DISC includes oligomerization 
and, consequently, two-step autoproteolytic cleavage (Medema et al. 1997; Muzio et 
al. 1998). The cleavage occurs at defined aspartate residues: the first cleavage step 
at Asp374 separates the p12 subunit from the remaining p43 and p41 (for 
procaspase-8a or -8b, respectively). The second cleavage step occurs at Asp384 
and Asp210/Asp216, which leads to the generation of p10, p18 and the prodomain 
p24/p26. The active heterotetramer p182-p102 can still be detected at the DISC 
indicating that the heterotetramer is produced directly at the DISC and then released 
into the cytosol (Lavrik et al. 2003). Recently it also has been reported that the fully 
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active caspase-8 heteroteramer p412-p102 cleaves procaspase-3 and Bid and 
thereby might also drive CD95-induced apoptosis without processing to the 
p182-p102 form (Hughes et al. 2009). In addition, recently the alternative way of 
caspase-8 activation has been reported by our group, which involves an alternative 
C-terminal cleavage product of procaspase-8, p30, generated by cleavage at Asp210 
(Hoffmann et al., 2009).  
It was reported that c-FLIPL plays an important role in procaspase-8 activation by 
heterodimerisation of the protease-like domain of c-FLIPL with the protease domain of 
procaspase-8 and 10, leading to their allosterical activation (Micheau et al. 2002; 
Chang et al. 2003; Yu et al. 2009). This heterooligomerisation between c-FLIPL and 
caspase-8 catalytic domains occurs more efficiently than homodimerisation of 
caspase-8 catalytic domains. This leads to an increase of procaspase-8 proteolytic 
activity by c-FLIPL.  
The activity of caspase-8 can be also regulated by posttranslational modifications 
(Fig. 5). Several studies have shown that phosphorylation at Y380 of procaspase-8 
inhibits CD95-induced caspase-8 activation (Cursi et al. 2006; Senft et al. 2007). For 
the TRAILR1 and CD95 DISC it has been reported that the full activation of 
procaspase-8 requires CUL3-RBX1-dependent polyubiquitination. Polyubiquitination 
of procaspase-8 at the DISC is followed by its translocation from the DISC into an 
ubiquitin complex, called aggresome (Jin et al. 2009). 
 
1.2.1.1.2.3. Procaspase-10 
Caspase-10 shares homologous DEDs with caspase-8 (Fig. 5). Caspase-10 is 
recruited to the DISC via DED interactions with FADD. Caspase-8 and caspase-10 
may regulate each other by competing for the binding to FADD DED at the DISC 
(Wang et al. 2001). Procaspase-10 is proteolytically activated at the DISC, however, 
whether caspase-10 can initiate apoptosis in the absence of caspase-8 is still elusive 
(Sprick et al. 2002). It has been shown that caspase-10 is also located at other 
DR-signaling complexes formed in response to DR stimulation. Interestingly, the 
substrate specificity of caspase-10 is different from that of caspase-8 (Wang et al. 
2007).  
Various autoimmune lymphoproliferative syndromes are associated with 
decreased caspase-10 function and thereby defective DR signaling. Procaspase-10 
is expressed at high levels in primary cells derived from the immune system but it is 
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present at low level or absent in many transformed cell lines. It was shown that mice 
and rats do not have the CASP-10 gene (Reed et al. 2003). 
 
1.2.1.1.2.4. c-FLIPL/S/R 
DR-mediated apoptosis can be regulated at the DISC by c-FLIP (also known as 
FLAME-1, I-FLICE, Casper, CASH, MRIT, CLARP or usurpin), which was originally 
found in the family of herpes viruses. Several splice variants of c-FLIP were found to 
exist on the mRNA level, but so far only three c-FLIP proteins have been identified: 
c-FLIPS, c-FLIPR
 
and c-FLIPL
 
(Irmler et al. 1997; Scaffidi et al. 1999; Golks et al. 
2005) (Fig. 5). All c-FLIP variants have two DEDs and function in a dominant-
negative way to block the recruitment to the DISC and the activation of procaspase-8 
(Krueger et al. 2001). c-FLIPS
 
has a similar structure as viral FLIP (v-FLIP), except 
that the two DEDs of the c-FLIPS
 
are followed by a short C-terminal extension of 
around 20 amino acids that seems to be crucial for its ubiquitylation and therefore its 
proteasomal degradation. c-FLIPR also contains two DEDs but lacks the additional 
C-terminal amino acids. c-FLIPL contains a longer C-terminal extension with a 
caspase-like region that is similar to procaspase-8 and procaspase-10 (Fig. 5). 
However, the C-terminal part of c-FLIPL lacks caspase enzymatic activity due to the 
substitution of several amino acids, such as the cysteine residue required for catalytic 
activity (Goltsev et al. 1997; Inohara et al. 1997).  
 
1.2.1.1.3. Two CD95 signaling pathways  
Cell death can be initiated by CD95 activation in two different ways (Scaffidi et al. 
1998; Barnhart et al. 2003). Type I cells release large amounts of active caspase-8 
from the DISC. This is sufficient to directly cleave and activate procaspase-3, -6, and 
-7. Effector caspases-3, -6, -7 cleave various cellular components as nuclear lamins, 
cytoskeleton proteins fodrin and gelsolin, and inhibitor of caspase-activated DNase 
(ICAD), thus activating caspase-mediated DNA degradation by DNase (Scaffidi et al. 
1998; Lavrik et al. 2005; Fulda 2009). 
 Type II cells, by contrast, produce a very low amount of active caspase-8 at the 
DISC. This, however, is sufficient to cleave the proapoptotic BH3 domain only 
containing Bcl-2 family member Bid to tBID (truncated Bid) (Li et al. 1998; Luo et al. 
1998). tBid translocates to the mitochondria where it induces the release of 
cytochrome c.  
Olga Shatnyeva 
 
29 
Introduction 
 
Figure 6. Two CD95 signaling pathways. Type I cells form high amounts of the DISC and 
active caspase-8 (left side). Type II cells form the DISC and active caspase-8 in lower 
amounts and require amplification of the apoptotic signal via mitochondria. Apoptosis in Type 
II cells can be blocked by Bcl-2 family members (right side) (adapted from (Krammer 2000)).  
This results in apoptosome formation and activation of procaspase-9. In a next 
step activation of effector caspases-3, -6 and -7 occurs (Fig. 6). Apoptosis in Type I 
cells can be induced independently of mitochondria. Deletion or overexpression of 
Type II pathway proteins (procaspase-9, Apaf-1) confirm a physiological role for the 
two pathway model (Scaffidi et al. 1998). Knockout studies in mice provide evidence 
that thymocytes are Type I and liver cells are Type II cells (Strasser 1995; Lacronique 
et al. 1996; Rodriguez et al. 1999).  
Recently, it has been reported that XIAP is a regulator of Type I and Type II cells. 
It was shown using XIAP knockout mice and double BID-XIAP knockout mice that 
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XIAP can convert cell death from Type II to Type I (Jost et al. 2009). However, this 
hypothesis has not been really brought in line with the original Type I/Type II 
definition (Scaffidi et al. 1998), which classifies CD95 signaling as Type I or Type II 
based on the amount of DISC formation.  
A number of CD95 signaling events in Type I and Type II cells have been 
described, which are controversially discussed. Upon initiation of signaling CD95 has 
been reported to form SDS- and β-mercaptoethanol-stable aggregates (Kischkel et 
al. 1995; Kamitani et al. 1997; Papoff et al. 1999) (Henkler et al. 2005) CD95 has 
been reported to be translocated to membrane rafts in Type I but not in Type II cells 
(Hueber et al. 2002; Eramo et al. 2004; Muppidi et al. 2004; Legembre et al. 2006). 
Another controversially discussed finding is that CD95 is internalized in Type I cells, 
which amplifies apoptosis induction (Algeciras-Schimnich et al. 2002).  
 
1.2.1.2. DR3 signaling 
DR3 shows close sequence similarity to TNFR1 (Chinnaiyan et al. 1996; Kitson et 
al. 1996; Marsters et al. 1996; Bodmer et al. 1997; Screaton et al. 1997). Upon 
overexpression, DR3 triggers responses that resemble those of TNFR1, namely, 
NF-κB activation and apoptosis. Like TNFR1, DR3 activates NF-κB through TRADD, 
TRAF2, and RIP and apoptosis through TRADD, FADD, and caspase-8. DR3 binds 
to Apo3L, which is related most closely to TNF (Marsters et al. 1998; Kabra et al. 
2001). 
 
1.2.1.3. TRAILR1 and TRAILR2 signaling 
TRAIL binds to TRAILR1 (DR4) and TRAILR2 (DR5). Both receptors are often co-
expressed in one cell type. Nonetheless, TRAILR2 seems to play a more important 
role than TRAILR1 in triggering apoptosis in cells expressing both receptors (Pan et 
al. 1997; Pan et al. 1997). Upon activation, TRAILR1 and TRAILR2 recruit FADD, 
procaspase-8 and procaspase-10 to their respective DISCs. Followed by the initiation 
of a caspase cascade which resembles the CD95 signaling pathway (Fig. 3) (Kuang 
et al. 2000; Sprick et al. 2000; Merino et al. 2006).  
A posttranslational modification, O-glycosylation of TRAIL receptors has been 
reported to increase TRAIL sensitivity by promoting ligand-induced receptor 
clustering and consequently procaspase-8 activation. Expression of 
O-glycosyltransferases correlates with sensitivity to TRAIL-mediated apoptosis in a 
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large number of tumor cell lines and represents a potential new biomarker for 
screening cancer patients for TRAIL-based clinical trials (Wagner et al. 2007). 
TRAIL has also been reported to promote activation of prosurvival proteins such 
as NF-κB, protein kinase B (PBK)/Akt, and MAP kinases through distinct, 
independent pathways (Secchiero et al. 2004). TRAILR1, TRAILR2, and TRAILR4 
have been shown to activate NF-κB via a TRAF-2-NIK-IKK complex (IκB kinase 
complex)-dependent signaling cascade, whereas TRAILR1 induces JNK/SAPK 
activation via a TRAF-2-MEKK1-MKK4 dependent pathway (Falschlehner et al. 
2007).  
 
1.2.1.4. TNFR1 signaling 
The TNFα/TNF-receptor signaling system consists of two distinct receptors, 
TNFR1 and TNFR2 (p75/CD120b). Three ligands are known: the membrane-bound 
TNFα (mTNFα), the soluble TNF-α (sTNFα), and the soluble lymphocyte-derived 
cytokine (LTα/TNFβ) (Wallach et al. 1999).  
While TNFR1 is considered to be a canonical DR, TNFR2 does not contain an 
intracellular death domain. To a great extent TNFR1 appears to be responsible for 
TNF signaling in most cell types. Studies of TNFR1-deficient mice have shown that 
TNFR1 is essential for TNF-induced apoptosis of pathogen-infected cells (Pfeffer et 
al. 1993; Zhao et al. 2000). TNFα plays a key role in inflammation and immunity, as 
well as in proliferation and differentiation (Wajant et al. 2003). It is mainly produced 
by mononuclear phagocytes and T cells in response to infection and inflammatory 
conditions, but also by other cell types, such as B cells, fibroblasts, and hepatocytes. 
Soluble and membrane-bound TNFα are biologically active, and while the soluble 
form acts as an effector molecule at a distance from the producer cell, the 
membrane-bound form likely has a specific role in localized TNFα responses. 
TNFR1 is primarily involved in mediating inflammation and not cell death. 
Engagement of TNFR1 by TNFα induces recruitment of RIP1, TRAF2, and c-IAP1/2 
to the receptor to form the membrane-bound complex I (Micheau et al. 2003). The 
presence of TRADD in this complex is controversial (Schneider-Brachert et al. 2004). 
It has been reported that complex I requires translocation of TNFR1 to lipid rafts, 
where several proteins in the complex undergo posttranslational modifications (Legler 
et al. 2003). In particular, RIP1 is polyubiquitinated at Lys377 by cIAP1 and cIAP2, 
which act as E3 ligase, a step required for the activation of NF-κB (Li et al. 2006). 
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These lysine 63-linked polyubiquitin chains of RIP1 are essential for the recruitment 
of TAK1 and IKK complexes to the TNF receptor complex (Ea et al. 2006).  
Two distinct pathways originate from the association of RIP1 and TRAF-2 to the 
receptor, whose balance determines the ultimate fate of the cell in response to TNFα 
(Wajant et al. 2001). The first pathway promotes NF-κB activation and signals 
through binding of the protein kinase TAK1 via interaction of the TAK1 complex, 
consisting of the TAK1 kinase and its associated TAK1-binding proteins 1/2/3 (TAB1, 
TAB2, and TAB3) with RIP1 lysine 63-linked polyubiquitin chains, resulting in TAK1 
kinase phosphorylation and activation. TAK1 proceeds to activate the catalytic IKK 
complex, comprising the three proteins IKKα (IKK1), IKKβ (IKK2), and IKKγ (NEMO), 
leading to phosphorylation of the NF-κB inhibitory protein IκBα. Phosphorylated IκBα 
is then degraded upon ubiquitination via the proteasome; allowing NF-κB to be 
translocated into the nucleus and initiate transcription of antiapoptotic genes such as 
c-FLIP, cIAP1, cIAP2, TRAF1, and TRAF2. Thus, ubiqutination of RIP1 dictates its 
survival signaling cascade. It has recently been published that cIAP1 and cIAP2 
directly ubiquitinate RIP1 and induce constitutive RIP1 polyubiquitination in cancer 
cells, thereby sustaining cancer cell proliferation (Ea et al. 2006). 
The second pathway originating from the association of RIP1 and TRAF-2 with the 
receptor leads to activation of JNK via the sequential activation of MEKK-1 and JNKK 
(JNK kinase). JNK phosphorylates and activates c-Jun, a component of the 
transcription factor complex termed activator protein-1 (AP-1). Transient JNK 
pro-death stimuli are normally inhibited by NF-κB regulated genes, such as xiap, 
which encodes the endogenous inhibitor of apoptosis, XIAP, and promotes cell 
survival (Tang et al. 2001). However, JNK-sustained activation mediates 
phosphorylation and activation of the E3 ubiquitin ligase Itch, which specifically 
ubiquitinates c-FLIP and promotes its proteasomal degradation, resulting in 
enhanced procaspase-8 activation and apoptosis (Chang et al. 2006). 
Activation of procaspase-8 and apoptosis initiation upon TNF stimulation has been 
explained by two different mechanisms, but both of them are still questioned. 
According to Micheau et al., activation of procaspase-8/10 occurs in Complex II 
which contains TRADD, TRAF2, RIP1, FADD, and procaspase 8/10. Complex II 
dissociates from complex I directly to the cytosol (Micheau et al. 2003). Alternatively, 
it was suggested that following the transient formation of complex I, the receptor is 
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probably internalized by endocytosis (Schneider-Brachert et al. 2006). It has been 
suggested that RIP1, TRAF2, and perhaps TRADD dissociates from TNFR1 during 
endocytosis, allowing the DD of RIP1 to interact with the DD of FADD, which, in turn, 
recruites procaspase-8 and -10.  
 
1.2.1.5. DR6 signaling 
DR6 is broadly expressed by developing neurons and required for normal cell 
death and axonal pruning in vivo. It also plays a role in lymphocyte development 
(Schmidt et al. 2003). APP was shown to be the ligand for DR6. APP-DR6 signaling 
leads to neurodegenration possibly via caspase-6 activation and contributes to the 
pathophysiology of Alzheimer’s disease (Nikolaev et al. 2009). 
 
1.2.2. Structures of CD95 and other death receptors 
Structural information about DRs is based on the structures of the TNFR1-TNFα 
complex (Banner et al. 1993), TNFR1 ectodomain (ECD) (Naismith et al. 1996) and 
intracelular domain (Sukits et al. 2001), herpes virus entry mediator (HVEM), 
Apo2L/TRAIL-TRAILR2 complex (Hymowitz et al. 1999; Mongkolsapaya et al. 1999; 
Cha et al. 2000), complex of FADD-CD95 DDs (Scott et al. 2009) and CD95 DD 
(Huang et al. 1996). These structures show that the ECD of DRs as well as that of 
other TNFR family members contain several cysteine-rich domains (CRD) which form 
elongated structures composed of loops tethered together by disulfide bridges 
(Fig. 7A). These receptors bind at the monomer-monomer interfaces of their trimeric 
ligands to form a complex consisting of three copies of the receptor and one trimeric 
ligand (Fig. 7B).  
The ligands of TNFRs are members of the TNF family. The ligands have been 
structurally characterized more thoroughly than the receptors. Initially the structure of 
TNF has been determined and so far supplemented by the structures of several other 
family members. These structures show that TNFs are homotrimeric globular proteins 
with distant structural homology to viral capsid proteins as well as to the complement 
protein C1q and to the NCI domain of collagen X (Jones et al. 1989; Shapiro et al. 
1998; Bogin et al. 2002). 
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Figure 7. Structural properties of Death Receptors (DR). A. Cartoon representation of 
TNFR1 extracellular domain with three cystein-rich domains (CRD) and disulfide bonds 
shown as yellow sticks (PDB ID 1tnr chain) B. Example of trimeric DR-ligand extracellular 
domains complex based on TNFR1-TNFα complex (PDB ID 1tnr).  
Most of the TNFRs are type I transmembrane proteins with the N-terminal signal 
sequence followed by the CRDs, a transmembrane helix and a C-terminal 
intracellular domain. Some of the family members are type III transmembrane 
proteins without a signal sequence. TNFRs are very divergent and have very low 
pairwise sequence identity. This divergence is a consequence of a nonglobular fold 
composed of cysteine-rich pseudorepeats. A typical CRD contains approx 40 
residues with 6 cysteins connected in a 1-2, 3-5, 4-6 pattern of disulfide linkages 
(Fig. 7A). 
Several TNFR family members have been determined to be preoligomerized by 
FRET, coimmunoprecipitation and FACS analysis (Siegel et al. 2000). This seems to 
be dependent on the N-terminal part of the first CRD, called PLAD. However, further 
biophysical characterization of the PLAD is necessary to understand its role in TNFR 
regulation. 
 
1.2.2.1. TNFR1 and TRAILR2 complexes 
Formation of TNFR-TNFα complexes has been largely derived from the structure 
of the LTα homotrimer bound to the ECD of TNFR1. Determination of the structure of 
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Apo2/TRAIL bound to DR5 by several groups confirmed that this binding mode 
(Fig. 9) is conserved for other multidomain TNFRs and showed that the structurally 
equivalent loops in other TNFRs are similar. 
 
Figure 8. Crystal structure of extracellular domain complex of TRAILR2-TRAIL (PDB ID 
1d0g). Corresponding TRAILR2-TRAIL monomers are shown in the same color. A. Side view 
of the complex (cartoon-surface representation). B. View on the complex from the first CRD 
of TRAILR2 (cartoon-surface representation). C. One receptor (cartoon representation) 
interacts with two ligands (surface representation). 
CRD2 and the first loop of CRD3 mediate most of the contacts to the ligand in both 
TNFR1-TNFα and TRALR2-Apo2L/TRAIL complexes. This is consistent with the 
observation that CRD2 is the most conserved region in TNFR1, HveA and TRAILR2. 
In both the TNFR1-TNFα and TRALR2-Apo2L/TRAIL complexes, the spacing of 
the C-termini of the receptors as they enter the cell form an almost equilateral triangle 
with sides of approximately 50 Å. This similarity in geometry suggests that this 
spacing is likely physiologically relevant and may be required for signaling. 
Modelling studies of other receptor-ligand complexes including CD95 (Bajorath 
1999; Bajorath 1999) and CD40 (Bajorath et al. 1995; Bajorath 1998) suggest that 
these receptors also interact with their ligands in a similar manner. 
 
1.2.2.2. CD95/Fas/APO-1 
DD complexes are key protein arrangements in the regulation of various cellular 
signaling events. The 'Death domain superfamily' includes DD, DED, CARD and 
pyrin domain (PYD). All of these domains are typically globular protein units that 
exhibit a characteristic six helix fold and are known to undergo homotypical 
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interactions with other death domains of the same family (Boldin et al. 1995; 
Chinnaiyan et al. 1995; Kischkel et al. 1995; Muzio et al. 1996; Tibbetts et al. 2003). 
 
Figure 9. Crystal structure of death domains complex of CD95 (green) and FADD (blue) 
(PDB ID 3ezq). A. Heterooctamer structure found in the crystal consisting of four molecules 
of CD95 DD and four molecules of FADD DD. B. Complex is formed via interactions of two 
extended helixes of CD95 DD. One FADD DD molecule interacts with only one CD95 DD in 
the region which was occupied by an extended helix of the CD95 DD. C. Octamer is formed 
by interaction of extended helixes of the CD95 DD. 
In the case of the CD95/FADD/procaspase-8 DISC the 'death domain network' is 
built by an interaction of the DD of CD95 with the DD of FADD, which also contains a 
DED to recruit procaspase-8 through homotypical DED interactions (Fig. 9). 
The structure of the CD95/FADD DD complex, which represents the first known 
structure of a 'death domain network', has been reported recently. The complex has 
been obtained in vitro by combining bacterial lysates of the overexpressed DDs. To 
solve the structure of the CD95/FADD DD complex a  broad crystallization effort was 
undertaken. The key observation was that the CD95 DD had undergone a significant 
opening transition in the CD95/FADD complex. This opening creates binding sites for 
the FADD DD that are absent in the closed form of CD95. The predominant 
CD95-CD95 association has also been observed in the structure. It is formed by stem 
helices and C-helices of the two CD95 DDs (Fig. 9C). Opening of CD95 provides the 
basis for both FADD DD binding and the formation of a regulatory bridge between 
CD95 molecules (Scott et al. 2009). 
The availability of crystal structures of several TNF family members facilitates the 
construction of homology models for the whole family. These models can be very 
useful for determining potential residues to mutate in order to identify the receptor 
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binding sites, for understanding tertiary structure and for the analysis of 
posttranslational modifications. 
 
1.2.3. Different forms and posttranslational modifications of CD95 
A number of reports on CD95 have suggested the presence of several forms of 
CD95, which have different molecular mass (Oehm et al. 1992; Peter et al. 1995). 
The presence of these forms can be explained by alternative splicing or by 
posttranslational modifications. 
 
 
Figure 10. Schematic representation of the domain organization of CD95. The CRD are 
shown in yellow, the transmembrane domain (TM) in blue, the DD in red. Potential 
glycosylation sites are depicted as schematic oligosaccharides, phosphorylation sites as 
black arrows, palmitoylation sites as green arrows. 
 
1.2.2.2.1. CD95 splice variants 
Alternative splicing of CD95 primarily results in the translation of soluble CD95 
protein or peptides (sCD95). There are six reported sCD95 isoforms. All of them lack 
the transmembrane region encoded in exon 6 of the CD95 gene. These sCD95 
variants are secreted and appear to have a dominant negative effect on CD95 
activation by interacting with CD95L. These splice variants are associated with 
different types of cancer (Cascino et al. 1995; Cascino et al. 1998). 
 
1.2.2.2.2. CD95 phosphorylation 
CD95 has been reported to be phosphorylated at Thr, Tyr and Ser in the PLAD 
and cystein-rich extracellular regions (Lautrette et al. 2006) (Fig. 10). In addition, 
CD95 is phosphorylated intracellulary at the area comprising amino acids 191-275 
(Fig. 10). The potential intracellular phosphorylation sites are Tyr232, Tyr291, as well 
as four Thr and two Ser located between amino acids 229 and 275. All of them lie in 
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the DD of CD95 and might influence apoptotic signaling via modulation of the binding 
of adaptor proteins. 
It has also been reported that CD95 might be phosphorylated by extracellular 
protein kinase C (PKC) (Lautrette et al. 2006). There are three potential sites for PKC 
in the extracellular region. The first one is located in PLAD. Therefore, 
phosphorylation of this site by ecto-PKC may directly modulate CD95L-independent 
oligomerisation of CD95 receptors and apoptosis signaling by blocking 
preassociation of the receptors. Two others are located in the ligand-binding region. 
Phosphorylation at this area might modulate CD95L binding to the receptor (Fig.10). 
 
1.2.2.2.3. CD95  S-palmitoylation  
Another possible modification of CD95 which has been reported is palmitoylation 
(Feig et al. 2007). Formation of CD95 SDS-stable aggregates has been shown to be 
regulated by palmitoylation of CD95 at cysteine 199. These aggregates were called 
hiDISC - high molecular weight DISC. In hiDISC procaspase-8 and FADD are 
suggested to be recruited to the CD95 DISC leading to caspase-8 activation.  
 
1.2.2.2.4. CD95 glycosylation 
CD95 is a 36 kDa membrane glycoprotein (Oehm et al. 1992). CD95 glycosylation 
has not been studied in detail so far. However, it is known that the apparent mass of 
CD95 increases from 36 to 45-54 KDa due to addition of variable oligosaccharide 
chains. CD95 contains three potential sites for N-linked glycosylation and one 
potential site for O-glycosylation. Glycosylation of CD95 has been demonstrated to 
comprise a high degree of sialylation (Peter, 1995). It has been shown that CD95 is 
present at least as 12 differently sialylated forms in different subclones of the B 
lymphoblastoid cell line BJAB and in the T leukemia cell line Jurkat. Removal of sialic 
acid residues from the surface of these cell lines increased their sensitivity to CD95-
mediated death (Peter et al. 1995; Keppler et al. 1999). 
Another interesting observation is that treatment with IFNγ increases the amount 
of N-glycosylated forms of CD95 in different cell lines, which results in higher 
expression of CD95 on the cell surface and consequently increases sensitivity to 
CD95-induced apoptosis. In another study, inhibition of enzymes of the glycosylation 
machinery and enzymatic removal of the glycans did not influence surface 
localization of CD95 (Dorrie et al. 2002). 
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1.3. Glycosylation 
Glycosylation plays an important role in many processes in an organism, from 
fertilization to ontogenesis and development. The main players of the glycosylation 
process are enzymes (glycosyltransferases and glycosidases) which ensure addition 
and removal of carbohydrates, respectively. 
Cell surface carbohydrates are major components of the outer surface of 
mammalian cells. Carbohydrate structures change drastically during mammalian 
development. Specific sets of carbohydrates are expressed at different stages of 
differentiation. In many instances these carbohydrates can be recognized as 
differentiation antigens by specific antibodies. In mature organisms, production of 
distinct carbohydrates is eventually restricted to specific cell types which results in 
cell type-specific carbohydrates. Aberrations in these cell surface carbohydrates are 
associated with various pathological conditions, including malignant transformation 
(Parodi 2000). 
 
1.3.1. The nature of carbohydrate diversity 
Carbohydrates are unique in their structural complexity. In contrast to nucleic acids 
and proteins, carbohydrates are linked in many different ways. One sugar residue 
could bind another sugar at three or four different positions of hydroxyl groups having 
either α- or β-isoconformations. These multiple binding abilities allow carbohydrates 
to have branches, unlike all other biological macromolecules, which contain almost 
exclusively linear structures. Because of this complexity, carbohydrate structures are 
very variable (Yarema et al. 2001). 
 
1.3.2. Different types of glycosylation and glycoproteins 
There are six classes of glycans (Fig. 11): 1) N-linked glycans attached to the 
amide nitrogen of Asn side chains; 2) O-linked glycans attached to the hydroxyl 
group of serine and Thr residues; 3) glycosaminoglycans attached to the hydroxyl 
group of serine; 4) glycolipids in which the glycans are attached to ceramide; 5) 
hyaluronan which is unattached to either protein or lipid; and 6) GPI anchors which 
link proteins to lipids through glycan linkages (Lowe et al. 2003). 
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Figure 11. Six classes of glycans. Representative examples of each distinct class of 
mammalian glycans are depicted schematically. The symbols used to denote each 
component monosaccharide within each glycan are described in the legend. Adapted from 
(Lowe et al. 2003). 
There are two types of protein-attached carbohydrates – O- and N-glycans 
(Fig. 11). In O-glycans, saccharides are attached to the hydroxyl groups of amino 
acids. In N-glycans, terminal N-acetylglucosamine is linked to the amide group of 
asparagine, forming an aspartylglucosamine linkage. Since the hydroxyl group 
originally attached to C-1 of the N-acetylglucosamine residue is removed during 
formation of this linkage, the amino group is directly attached to C-1. 
N-glycans can be classified into three different groups according to their 
structures: high mannose, hybrid and complex (Fig. 12). All three types contain a 
common structure “core”. This core portion is composed of di-N-acetylchitobiose and 
three mannose residues, in which the latter form branches. In high mannose 
oligosaccharides two to six more mannose residues are attached to this core 
(Fig. 12) (Parodi 2000). 
Complex oligosaccharides always contain three mannose residues. The outer two 
α-mannose residues are linked to N-acetyllactoseamine (Fig. 12). This is followed by 
sialic acid residues or additional N-acetyllactosamine residues. Hybrid N-glycans 
contain more than three mannose residues, but also contain an N-acetyllactoseamine 
side chain which is attached to α1-3-linked mannose. This type of oligosaccharide is 
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formed when the high mannose oligosaccharide is partially processed and additional 
sugars are attached. 
 
Figure 12. Mammalian N-glycan synthesis. The synthesis starts with dolichol 
pyrophosphate (Dol-P-P) and ends with final multiantennary structure. Potential branching 
patterns are made possible by the actions of several distinct glycosylttransferases 
(represented by multiple arrows without labels). The general category of each class of N-
glycan is identified at top. The subcellular location where the steps of the synthesis occur is 
identified at the bottom. Symbols used to denote each component monosaccharide are 
identified at the legend  the bottom. Adapted from (Lowe et al. 2003). 
Complex, high mannose and hybrid types of N-glycan share a common core 
structure because all three types are synthesized from a common precursor. The 
biosynthesis of N-glycans is initiated by the addition of a precursor sugar which is 
attached to dolichol. This lipid-linked oligosaccharide is composed of nine mannoses, 
three glucoses and two N-acetylglucosamine residues. This dolichol-linked 
intermediate is then transferred as a block to an asparagine residue of a polypeptide. 
This step also occurs in the synthesis of complex N-glycans. The conversion of a 
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high mannose oligosaccharide to a complex one requires multiple steps, involving 
trimming and then addition of monosaccharides.  
The processing of N-glycans is initiated by removal of three glucose residues in 
the endoplasmic reticulum (ER). After that, one α-2 linked mannose is removed and 
the glycoprotein is transported to the cis-Golgi. If the first step does not take place 
properly, a chaperone that recognizes malformed structures either forces the 
glycoprotein back into ER or subjects it to proteolytic digestion. After proper trimming 
the oligosaccharide is processed by α-mannosidase I to remove three more 
α1-2-linked mannose residues. The resultant oligosaccharide can now be an 
acceptor for N-acetylglucoseaminyltransferase I (Parodi 2002). 
 
1.3.3. Enzymes associated with glycosylation 
There are two types of enzymes associated with glycosylation – 
glycosyltransferases (GT) and glycosyl hydrolases/glycosidaes (GH). GT catalyze 
glycosidic bond formation using sugar donors containing a nucleoside phosphate or a 
lipid phosphate leaving group. Nowadays for H. sapiens 250 GT genes and around 
250 GH genes are discovered. 
The known GT from all species can be classified in 91 families and all GH can be 
classified in 115 families (Cantarel et al. 2009). GT plays an important role during 
embryogenesis and ontogenesis. This has been shown for many GT using knockout 
mice. Deficiency for many GT is associated with embryonic lethality and different 
disorders. Correspondingly, many human genetic defects in glycan formation are 
associated with diseases. These diseases were in some cases the result of the 
deficiency on GTs or they were associated with defects in glycan structure (Coutinho 
et al. 2003). 
Biochemical and structural studies indicate that glycosyltransferases are partially 
segregated into distinct compartments within the secretory pathway. Most information 
relevant for the retention of glycosyltransferases within specific Golgi compartments 
is derived from experiments done with α2–6 sialyltransferase (ST6Gal-I), a β1-4 
galactosyltransferase (GalT-I), and an N-acetylglucosaminyltransferase (GlcNAcT-I). 
Two models have been proposed to account for retention of specific 
glycosyltransferases to specific Golgi subcompartments. The first of these, termed 
the kin-recognition model, suggests that members of a set of glycosyltransferases 
have evolved to localize to a specific compartment will aggregate with themselves in 
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a multimeric complex, after arriving at the proper Golgi compartment. This 
hypothetical process would involve homo- and hetero-oligomerization through 
interactions between the stem regions and/or transmembrane segments of the 
glycosyltransferases in the aggregate (Colley 1997).  
A second model proposes that each glycosyltransferase sorts itself into the proper 
Golgi location by virtue of the length of its transmembrane segment, which will retain 
the enzyme once it reaches the proper compartment during the enzyme's transit 
through the secretory pathway. This model was formulated largely on the basis of 
experiments involving ST6Gal-I, where the length of the membrane-spanning domain 
appears to play an important role in Golgi retention.  
GHs are classified into families according to their amino acid similarities (Vocadlo 
et al. 2008). These enzymes also play an important role in N-glycoprotein synthesis, 
but they are not considered as important as GTs. However,  deficiencies of GHs are 
associated with serious disorders in humans. Hereditary erythroblastic multinuclearity 
with a positive acidified-serum lysis test (HEMPAS) is an autosomal recessive 
disorder of glycosylation. HEMPAS is characterized by the lysis of red cell 
progenitors, hyperplasia of erythroid precursors, multinucleated erythroblasts and 
anemia. Red cells from HEMPAS patients contain defective glycoproteins. Using 
knockout mice it has been shown that deficiency on GHs such as α-mannosidase II 
and α-mannosidase IIx are associated with autoimmune diseases, dyserythropoiesis, 
spermatogenic failure and male sterility (Chui et al. 1997; Akama et al. 2002). 
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1.4. The aim of the study  
The CD95 (APO-1/Fas)-mediated apoptotic pathway is one of the best-studied DR 
pathway. Significant progress has been achieved in the understanding of CD95-
mediated events: DISC formation, caspase activation and Type I/Type II signaling. 
However, the role of CD95 modifications in signaling is still poorly understood. The 
aim of this study was to unravel the molecular mechanism how glycosylation of CD95 
influences DISC formation and apoptosis induction. In particular, the question was 
which step of CD95 DISC formation is dependent on the proper glycostructure of 
CD95: the trimerization of CD95, the binding of the ligand or the maintenance of the 
fine structure of the CD95 DISC complex. Furthermore, another challenging question 
was whether CD95 glycosylation might be a reason for the differences in Type I and 
Type II signaling. Finally, based on previous reports on the degree of CD95 
sialylation, which is a crucial factor for sensitivity and resistance of BJAB cells 
towards CD95-induced apoptosis, our goal also was to understand if this finding can 
be applied to a wide panel of cancer cell lines and to understand the exact molecular 
mechanism of this phenomenon. 
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals 
All chemicals for which the producer is not specified were purchased from the 
following companies: Fluka (Neu-Ulm, Germany), Merck (Darmstadt, Germany), Roth 
(Karlsruhe, Germany), Sigma-Aldrich (Steinheim, Germany) or Serva (Heidelberg, 
Germany).  
 
2.1.2. Buffers and solutions 
Name  Final concentration Content 
Triton X-100 Lysis buffer: 20 mM 
137 mM 
1% (v/v) 
2 mM 
1 mM 
1 tablet 
1.5 M Tris-HCl pH 7.4 
NaCl 
Triton X-100 
EDTA 
PMSF 
Protease inhibitor cocktail 
(Roche (Mannheim, Germany)) 
PBS: 137 mM 
8.1 mM 
2.7 mM 
1.5 mM 
NaCl 
Na2HPO4 
KCl 
KH2PO4 pH 7.4 
TBE (10x): 0.45 M 
0.45 M 
10 mM 
Tris-Base 
Boric acid (“ice cold”) 
EDTA pH 8.3 
Reducing sample buffer (2x): 20% (v/v) 
3% (w/v) 
20 mM 
10% (v/v) 
0.10 mg/ml 
Glycerin 
SDS 
TrisHCl pH 6.8 
β-Mercapto EtOH 
Bromophenol blue 
Running buffer (SDS PAGE): 25 mM 
0.19 M 
1% (w/v) 
Tris-Base 
Glycine 
SDS 
Western blot transfer buffer: 25 mM 
0.19 M 
20% (v/v) 
Tris 
Glycine 
MeOH 
Western-blot strip buffer 62.5 mM 
100 mM 
2% (w/v) 
Tris-HCl pH 8.0 
β-Mercapto EtOH 
SDS 
PBS-T solution 0.1% (v/v) Tween 20 in PBS 
ACK buffer (pH 7.2) 1 mM 
0.5 mM 
155 mM 
KHCO3 
EDTA 
NH4Cl 
SSC buffer 3 M 
0.3 M 
NaCl 
Na3-citrate 
10 x HBS (pH 6.5) 1.4 M  
100 mM  
500 mM  
NaCl 
KCl 
HEPES 
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20 mM  
22.2 mM  
 
Na2HPO4 
Glucose 
 
ELISA Coating buffer  
(pH 9.6) 
100 mM 
 
Na2CO3 
 
ELISA Washing buffer: 0.05 % (v/v) Tween 20 in PBS 
FACS buffer: 10 % (v/v) FBS in PBS 
 
2.1.3. Commercial kits  
Name Experimental purpose Producer 
BCA Assay Protein content measurement Pierce (Bonn, 
Germany) 
Pro-Q Diamond 
Phosphoprotein Gel Stain 
Selective staining of phosphoproteins in 
polyacrylamide gels 
Invitrogen  
(Karlsruhe, 
Germany) 
Reverse transriprion system Synthesis of single-stranded cDNA from 
total or poly(A)+ isolated RNA 
Promega 
(Mannheim, 
Germany) 
High Fidelity PCR Kit PCR  Roche 
(Mannheim, 
Germany)  
Gel Extracton Kit DNA fragments purification ready for 
direct use in all applications 
Qiagen (Hilden, 
Germany) 
Plasmid Maxi Kit Preparative scale plasmid isolation Qiagen (Hilden, 
Germany) 
RNeasy Protect Mini Kit Total RNA isolation Qiagen (Hilden, 
Germany) 
Trypsin EDTA solution Detachment of the adherent cells/ cell 
culture 
Gibco BRL 
(Karlsruhe, 
Germany) BRL 
Western LightningTM 
Chemiluminescence Kit 
Enhancement of the chemiluminescence Perkin Elmer 
(Jügesheim, 
Germany) 
QuikChangeIIXL Site-
Directed Mutagenesis Kit 
Generation of the mutants Stratagene (La 
Jolla, USA) 
 
2.1.4. Biological materials 
2.1.4.1. Bacterial strains and vectors 
E. coli strains Plasmid/ Resistance Experimental purpose 
XL10- Gold 
(Stratagene (La Jolla, USA)) 
pIRES-CD95/ ampicilin,  
pKEX-CD95/ ampicillin 
Mammalian host protein 
expression vector 
containing an IRES element 
and - cDNA of human CD95.  
Generation of the CD95 
glycomutants 
DH5α pKEX-CD95/ ampicillin 
pEGFP/ ampicillin,  
pIRES-CD95 and CD95 
glycomutants.  
Amplification of the plasmids 
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2.1.4.2. Eukaryotic cell lines 
Cell line Characteristics 
Jurkat16 (Schneider et al. 1977)  Human T-cell leukaemia line 
Jurkat A3 Human T-cell leukaemia line 
CEM (Foley et al. 1965) Human T-cell leukaemia line 
SKW6. 4 (Ralph et al. 1983) Human B lymphoblastoid line 
Hut 78 (J Exp Med 1981;154:1403) Human T cell lymphoma/ Derived from 
patient with Sezary syndrome  
BJAB EBV-negative Burkitt-similar lymphoblastoid 
human cell line  
HeLa (Scherer et al. 1953) Human cervix epitheloid carcinoma 
 
2.1.5. Cell culture media 
2.1.5.1.Media for bacteria 
Medium type Content 
LB (Luria-Bertani) 
 
 
10 g/l casein hydrolysate 
5 g/l yeast extract 
10 g/l NaCl 
pH = 7.2; adjusted with 1N NaOH 
Medium was supplemented with 30 µg/ml 
ampicillin for selection pressure 
SOC medium (100ml) 2 ml of filter-sterilized 20% (w/v) glucose 
98 ml of SOB medium 
SOB Medium 
 
20.0 g/l tryptone 
5.0 g/l yeast extract 
0.5 g/l of NaCl 
10 ml/l of filter-sterilized 1 M MgCl2 
10 ml/l of filter-sterilized 1 M MgSO4 
 
 
2.1.5.2. Cell culture media 
Cell type Culture medium 
Peripheral blood human T cells RPMI-1640 medium supplemented with 25 
U/ml of IL-2 
Jurkat16, Jurkat A3, CEM, SKW6. 4, Hut 78, 
BJAB 
RPMI-1640 medium 
HeLa DMEM 
 
Media were supplemented with 10% (v/v) FBS and 0.5% penicillin-streptomycin. 
All media and supplementary products were purchased from Gibco BRL (Karlsruhe, 
Germany).  
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2.1.6. Antibodies 
2.1.6.1. Primary antibodies 
Name  
(catalogue number) Antigen Serum / Isotype 
Producer, 
Reference 
Anti-GM130 (371-990) 
(CB1008) 
GM130 Rabbit polyclonal IgG Calbiochem (La 
Jolla, CA, USA) 
Calreticulin 
(PA3-900) 
Calreticulin Rabbit polyclonal IgG Affinity Bioreagents 
(Dublin, OH, USA) 
Anti-α-Tubulin α-Tubulin Mouse monoclonal 
IgG1 
 Sigma-Aldrich 
(Steinheim, 
Germany) 
Anti-CD95 (C20) CD95 Rabbit polyclonal Santa Cruz 
Biotechnology 
(Heidelberg, 
Germany) 
Anti-APO-1 CD95 Mouse monoclonal 
IgG3 
(Trauth et al. 1989) 
Anti-CD95 CD95 Rabbit polyclonal Santa Cruz 
Biotechnology 
(Heidelberg, 
Germany) 
Anti-Caspase-8 (C15) Caspase-8 Mouse monoclonal, 
IgG2b 
(Scaffidi et al. 1997) 
Anti- FADD (1C4) FADD Mouse monoclonal,  
IgG1 
(Scaffidi et al. 2000) 
Anti-cFLIP (NF6) c-FLIP Mouse monoclonal, 
IgG1 
(Scaffidi et al. 1999) 
Anti-Bid (44-433) Bid p15 Rabbit polyclonal Biosource 
(Invitrogen) 
(Karlsruhe, 
Germany) 
Anti-Caspase-3 Caspase-3 Rabbit polyclonal Cell Signaling  
(Danvers, MA, USA)  
(Danvers, MA, USA) 
Technology 
Anti-ERK (MK12) ERK Rabbit polyclonal BD Transduction 
Laboratories 
(Heidelberg, 
Germany) 
Anti-Actin Actin Mouse monoclonal, 
IgG2a 
 Sigma-Aldrich 
(Steinheim, 
Germany) 
Anti-JNK JNK1 Rabbit polyclonal Santa Cruz 
Biotechnology 
(Heidelberg, 
Germany) 
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2.1.6.2. Secondary antibodies 
Name Antigen Producer 
Secondary HRP-conjugated Goat polyclonal IgG anti-
rabbit IgG 
 Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Secondary HRP-conjugated Donkey polyclonal IgG 
anti-goat IgG 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Secondary HRP-conjugated Goat polyclonal IgG 
anti-mouse IgG 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Secondary HRP-conjugated Goat polyclonal IgG 
anti-mouse IgG 
Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Alexa-594 Goat polyclonal anti-mouse 
IgG 
Molecular Probes 
(Invitrogen) (Karlsruhe, 
Germany) 
Alexa 488 Sheep polyclonal anti-rabbit 
IgG 
Molecular Probes 
(Invitrogen) (Karlsruhe, 
Germany) 
 
2.1.7. Chemical reagents and antibodies used for cell treatment 
Name and 
abbreviation 
Final oncentration 
range 
Stock solution Producer 
Sodium azide (Az) 1-100 µg/ml 1 mg/ml in H2O  Sigma-Aldrich 
(Steinheim, 
Germany) 
Tunicamycin 2 µg/ml 200 µg/ml Calbiochem (La 
Jolla, CA, USA) 
DMM 2 mM In H2O Calbiochem (La 
Jolla, CA, USA) 
N-glycosidase F 10 U In H2O Roche (Mannheim, 
Germany) 
VCN 100 mU In PBS  Sigma-Aldrich 
(Steinheim, 
Germany)  
Staurosporine 1 µM 1 mM in DMSO  Sigma-Aldrich 
(Steinheim, 
Germany)  
Puromycin 1 µg/ml 10 mg/ml in H2O  Sigma-Aldrich 
(Steinheim, 
Germany) 
 
2.1.8. Fluorescent probes  
Name and 
abbreviation 
Usage Final 
concentration 
Stock 
solution 
Producer 
Propidium iodide 
(PI) 
Plasma 
membrane 
permeability 
indicator 
5 µM 2 mM in PBS  Sigma-Aldrich 
(Steinheim, 
Germany) 
DAPI Detection of 
single nucleic 
acid molecules 
0.125 µg/ml in 
2x SSC 
0.25 mg/ml in 
H2Odd 
 Sigma-Aldrich 
(Steinheim, 
Germany)  
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Generally all stock solutions were stored as aliquots at –20 oC. PI stock solution 
was stored at 4 oC.  
 
2.1.9. Molecular biological materials  
2.1.9.1. Primers 
Name Primer sequence (5’- 3’)  
N118QF GACATGGCTTAGAAGTGGAAATACAGTGCACCCGGACC 
N118QR CTGTACCGAATCTTCACCTTTATGTCACGTGGGCCTGG 
N136QF ACCAAGTGCAGATGTAAACCAAACTTTTTTTGTCAGTCTACTGTATGTGAACA 
N136QR TGTTCACATACAGTAGACTGACAAAAAAAGTTTGGTTTACATCTGCACTTGGT’ 
T214QF GAAAACCAAGGTTCTCATGAATCTCCACAGTTAAATCCTGAAACAGTGGCAATAAAT 
T214QR ATTTATTGCCACTGTTTCAGGATTTAACTGTGGAGATTCATGAGAACCTTGGTTTTC 
N223QF  TTAAATCCTGAAACAGTGGCAATACAGTTATCTGATGTTGACTTGAGTAAAT 
N223QR ATTTACTCAAGTCAACATCAGATAACTGTATTGCCACTGTTTCAGGATTTAA 
FasIF  ATGCTGGGCATCTGGACCCT 
FasIR  GCCATGTCCTTCATCACACAA 
FasIIF  CATGGCTTAGAAGTGGAAAT 
FasIIR  ATTTATTGCCACTGTTTCAG 
FasIIIF  AAATTTATCTGATGTTGACT 
FasIIIR  TCTAGACCAAGCTTTGGATTTC 
All FasXXX primers are taken from (Cascino et al. 1995). 
 
2.1.10. Instruments 
Name Producer 
Semi-Dry blotting system: 
- Power supply, Consort E865 600V-500mA 
- Semi-dry transfer cell Trans-Blot SD 
Bio-Rad (München, Germany) 
Laminar chambers SG600 Baker Company (Maine, USA) 
Flow cytometers: FACScan, FACSCalibur 
and FACSCantoII 
BD Transduction Laboratories (Heidelberg, 
Germany) 
Agarose gel electrophoresis apparatus Gibco BRL (Karlsruhe, Germany) BRL 
Water baths Kotterman, B. Braun 
Thermostated hot-block 5320 Eppendorf (Wesseling-Berzdorf, Germany) 
Thermomixer Compact Eppendorf (Wesseling-Berzdorf, Germany) 
Thermocycler DNA Engine DYAD MJ Research (Ramsey, Minnesota, USA ) 
Light microscope ID 02 Zeiss (Göttingen, Germany) 
Fluorescence microscope Leica (Wetzlar, Germany) 
Confocal microscope Leica (Wetzlar, Germany) 
CO2-cell culture incubator Forma Scientific (Thermo) (Dreieich, 
Germany) 
Microwave oven HMG 730B Bosch (München, Germany) 
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Polyacrylamide gel electrophoresis 
apparatus PROTEAN II Cell 
Bio-Rad (München, Germany) 
Electrophoresis power supply PS 500 Renner (Dannstadt - Schauernheim, 
Germany) 
Bacteria culture incubator/shaker CH-403 Infors AG (Bottmingen, Switzerland)  
Spectrophotometer, BioPhotometer Eppendorf (Wesseling-Berzdorf, Germany) 
Quartz cuvettes Suprasil Hellma (Müllheim, Germany) 
Developing system for Roentgen films Curix 
160 
Agfa ( Mortsel, Belgium) 
Gel documentation system Bio-Rad (München, Germany) 
Analytical and precision balances Sartorius (Göttingen, Germany) 
Neubauer cell-counting chamber Brand (Wertheim Germany) 
Centrifuges: 
- Biofuge Fresco 17 
- Biofuge A 
- Megafuge 3. 0R 
- Sorvall Evolution RC 
 
Heraeus (Hanau, Germany) 
Heraeus (Hanau, Germany) 
Heraeus (Hanau, Germany) 
Kendro (Langenselbold, Germany) 
 
2.1.11. Software 
The following software was used: Microsoft Office, Adobe Photoshop 9.0, 
CellQuestPro4.0, BioEdit 5.0.9, CSS-Palm2, NetPhos 2.0, NetPhosK 1.0, NetCGlyc 
1.0, CSS-Palm 2.0, NetNGlyc 1.0, NetOGlyc 3.1. 
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2.2. Methods 
2.2.1. Standard procedures for eukaryotic cell cultures 
2.2.1.1. Cell culture 
All cell lines were propagated at 37oC in an incubator with a humidified 5% CO2 
atmosphere. Cells were grown as suspension culture and maintained by addition or 
replacement of fresh medium (every 2-3 days). Cell density was adjusted to 
1.0-2.5 x 105 cells/ml and monitored with the use of a Neubauer cell counting 
chamber. Cells were cultured in the type of medium specified before (2.1.5.2.).  
 
2.2.1.2. Maintenance of cell culture stocks 
To maintain genetically unchanged stocks of cell lines, the cells were stored in 
liquid nitrogen (-196oC). The aliquots were thawn according to need.  
 
2.2.1.2.1. Freezing cells 
Cells (1-2 x 106 cells/ml) were centrifuged for 5 min at 1500 rpm, 4oC, cooled on 
ice and suspended in FBS supplemented with 10% DMSO. After transfer into 2 ml 
cryovials the cell suspensions were stored overnight at -20oC, transferred to -80oC for 
2-3 days, and finally placed into liquid nitrogen (-196oC) for further storage. A slow 
gradient of lowering freezing temperatures should limit the extent of possible 
damage.  
 
2.2.1.2.2. Thawing cells 
The thawing procedure is characterized by a rapid increase in temperature and 
fast exchange of culture medium in order to avoid toxic effects of the high DMSO 
content. Directly after thawing, cells were transferred into 25 ml of pre-warmed 
culture medium and centrifuged for 5 min at 1500 rpm. Cells were then suspended in 
25 ml of fresh medium for further culture.  
 
2.2.1.3. Isolation and culture of human peripheral T cells 
Human peripheral T cells were prepared by Ficoll-Plaque density centrifugation, 
followed by rosetting with 2-amino-ethylisothyo-uronium-bromide-treated sheep red 
blood cells. 1 ml of heparin (Braun) was added to 500 ml of whole blood to inhibit 
clotting. 30 ml of blood was carefully layered onto 15 ml of pre-warmed (37oC) Ficoll 
solution (Biochrom) and centrifuged (2420 rpm, 20 min, RT, without breaks). The 
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leukocytes (a ring between the phases) were collected and washed 2 times with pre-
warmed, sterile PBS or RPMI medium (500 g, 10 min, RT, slow breaking - ”6”) and 
suspended in 200 ml of RPMI medium. The cell suspension was depleted of 
macrophages and monocytes (i. e. monodepletion) by their adhesion to plastic 
culture dishes (two 500 ml cell culture flasks) after 1 hour of incubation in a cell 
culture incubator. Non-adherent cells were collected, spun down (500 g, 10 min, RT) 
and suspended in RPMI medium (cell density: 1 x 107 cells/ml). Next, cells were 
mixed in a 2:1 ratio with 4% AET-erythrocytes for a “rosetting” reaction. The mixture 
was centrifuged (500 g, 10 min, RT, slow breaking – “2”). The pellet (containing 
“rosettes”) was resuspended, carefully layered on top of prewarmed Ficoll solution 
and centrifuged for 20 min at 2420 rpm and RT (without breaks). The pellet, 
consisting of T cells and erythrocytes, was washed with prewarmed PBS or medium 
(500 g, 10 min, RT, slow breaking - ”6”). The erythrocytes were lysed by addition of 
4x volume (acc. to the pellet) of ACK buffer. The lysis is indicated by a color change 
of the mixture from turbid light red to clear dark red. Subsequently, cells were washed 
(2 times) with prewarmed PBS or medium, resuspended in 50 ml of RPMI, counted 
and diluted to a concentration of 2 x 106 cells/ml. For activation, resting T cells were 
cultured at a concentration of 2 x 106 cells/ml in the presence of 1 µg/ml PHA for 16 
h. T cells were then cultured in RPMI medium supplemented with 10% FCS and 
25 U/ml IL-2 for six days (day 6 T cells). All experiments were performed with T cells 
isolated from at least three different healthy donors.  
 
2.2.2. Cell biological methods 
2.2.2.1. Transfection of eukaryotic cells 
2.2.2.1.1. Transfection with Fugene for generation of stable HeLa cell lines 
HeLa cells were grown to 50% confluence in 10 cm cell culture dishes. 5 µg of 
plasmid DNA were mixed with 100 µl of OPTIMEM. The volume of Fugene was 
calculated with the ratio 1 µg: 3 µl (DNA:Fugene). 15 µl of Fugene were added to 
300 µl of OPTIMEM and incubated for 5 minutes. Next, DNA and Fugene in 
OPTIMEM were mixed and incubated for another 15 minutes. Afterwards the mix was 
added to the cells after the medium has been changed. The cells were harvested 
after 36-48 hours. 
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2.2.2.1.2. Ca3(PO4)2 method 
HeLa cells were grown to 70-80% confluence in 10 cm cell culture dishes. 20 µg 
plasmids DNA were mixed with 1 ml HBS and 50 µl 2.5 M CaCl2 were added. After 15 
min of incubation the mix was added to the cells together with fresh media. Cells 
were harvested after 36 hours.  
 
2.2.2.2. Analysis of neuraminidase-treated cells  
Cells were harvested and washed in digestion buffer (20 mM Hepes, pH 7.0, 
140 mM NaCl). The cells were then resuspended in digestion buffer at a volume of 
1ml and at a density of 1 x 107 cells/ml. 100 mU/ml of Neuraminidase from Vibrio 
cholerae were added to the cells. Cells were incubated for 1 hour at 37oC, 5% CO2, 
and then washed with complete medium. Control cells were treated with digestion 
buffer only. Cells were analyzed for sensitivity to CD95-mediated apoptosis as 
described later. Protein lysates were also prepared from 1 x 107 cells and analyzed 
by Western blot.  
 
2.2.1.3. Inhibition of glycosylation  
The the mannosidase I inhibitor, 1-deoxymannojirimycin (DMM) was dissolved in 
water. The inhibitor tunicamycin, which completely inhibits N-glycosylation was 
dissolved in DMSO. Inhibitors were added at final concentrations of 2 mM for DMM 
and 2 µg/ml for tunicamycin. After a 24 h incubation, fresh glycosidase inhibitor was 
added to the cells at the same final concentrations. To control cells, only an 
equivalent amount of water or DMSO was added. The cells were harvested after 
48 h, and surface expression of CD95 was measured by FACS. Protein lysates were 
prepared for Western blot analysis and the cells were tested for sensitivity to CD95-
mediated death as described later.  
 
2.2.2.4. Cell death analysis 
The samples were analyzed using flow cytometric methods. Dying cells shrink and 
become more granular, resulting in a lower forward scatter index (FSC) and an 
increased side scatter index (SSC), respectively. Loss of membrane impermeability 
can be monitored by the use of propidium iodide (PI) staining (SSC/strength of PI 
emission signal). PI is not penetrating living cells but stains nuclei of dead cells 
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fluorescent red. Briefly, cells were centrifuged at 2000 rpm for 5 min (Biofuge, 
Heraeus (Hanau, Germany)), washed with PBS, suspended in PBS and stained by 
mixing with the equal volume of PI solution (5 µg/ml in PBS). Next, cells were 
immediately subjected to FACS analysis (PI excitation wavelength is 535 nm, 
emission wavelength 617 nm). Experimental results are presented as percentage of 
“specific cell death”, calculated according to the following formula:  
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2.2.2.5. Cell surface staining 
To analyze the surface expression of CD95, 5 x 105 cells were resuspended in 
100 µl of FACS buffer and incubated with 10 µg/ml of anti-APO-1 antibodies or with 
FII23 antibodies as isotype control for 15 min on ice. The cells were washed with 
FACS buffer, centrifuged and resuspended in 100 µl of FACS buffer containing 
PE-conjugated anti-mouse IgG antibody and incubated on ice for 15 min. The cells 
were washed with FACS buffer and resuspended in 300 µl of FACS buffer containing 
1 µg/ml PI. The staining was analysed by flow cytometry. The population was gated 
on living cells and the staining of isotype control was compared to the surface 
staining with anti-APO-1 antibody.  
 
2.2.2.6. Immunostaining of cultured cells 
5 x 105 HeLa cells were plated on autoclaved 12-mm coverslips into 12 -well plates 
and were grown overnight. Next morning they were washed with PBS and fixed with 
3% PFA in PBS. Afterwards they were washed with PBS for 3 times. Membranes 
were permeabilized for 5 min with 0.1% Triton X-100 and washed 3 times with PBS. 
Blockage of uspecific signals was done with different 10% serums dependent of 
secondary antibodies. Staining with primary antibodies diluted in PBS was performed 
in 50 µl for 1 hour at RT. Cells were washed 3 times with PBS for 5 min. Next, cells 
were stained with diluted in PBS secondary antibodies for 1 hour and washed 3 times 
with PBS. Nuclei were stained with DAPI for 5 minutes and cells were washed with 
PBS. Last, cells were put to the objective glasses with Fluoromount G mounting 
media. Stainings were analyzed by fluorescence and confocal microscopy.  
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2.2.3. Biochemical methods 
2.2.3.1. Western Blot and SDS-PAGE 
Cells were lysed in TritonX-100 lysis buffer and protein concentration was 
measured by BCA Assay (Pierce (Bonn, Germany), USA). Aliquots of cell lysates 
were resolved by SDS-PAGE (180 V, 25 mA, 1 hour), transferred onto nitrocellulose 
membranes (Pharmacia, USA) using a semi-dry system (transfer conditions: 
0.5 mA/cm2; 2 h) and blocked by 1 hour washing in blocking solution (5 % powdered 
milk or 5% BSA in PBS-T). Blots were then incubated with the respective primary 
antibodies (suspended in 1% milk or 3% BSA in PBS-T) (2 h at room temperature or 
overnight at 4oC) and washed (3 x 15 min) with PBS-T solution. After staining with 
horseradish peroxidase-conjugated secondary antibodies (1 h at room temperature) 
and washing with PBS-T solution (3 x 15 min), the signal was detected by enhanced 
chemiluminescence using Western Lightning Chemiluminescence Reagent 
(PerkinElmer, USA) according to the manufacturer’s instructions. Signal intensities 
were quantified by standard scanning densitometry with the NIH Image program, 
version 1. 36b.  
Separation Gel, 10% acrylamide (20ml) 
Reagent stock Volume (ml) 
30% Acrylamide mix 6.7 
1.5 M TrisHCl (pH 8.8) 5 
10% SDS 0.2 
10% APS 0.2 
TEMED 0.008 
H2O 7.9 
 
Stacking Gel (5ml) 
Reagent stock Volume (ml) 
30% Acrylamide mix 0.83 
1.5 M TrisHCl (pH 6.8) 0.68 
10% SDS 0.2 
10% APS 0.2 
TEMED 0.008 
H2O 3.4 
 
 
2.2.3.2. Preparation of total cellular lysates 
1 x 108 cells were washed twice in 1 x PBS and subsequently lysed in buffer A 
(20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride (Sigma-Aldrich (Steinheim, Germany)) protease inhibitor cocktail (Roche 
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(Mannheim, Germany), Switzerland), 1% Triton X-100 (Serva, Germany) and 10% 
glycerol) (stimulation condition) or lysed without treatment (unstimulated). 
 
2.2.3.3. N-glycosidase F treatment of protein lysates 
For N-glycosidase F treatment 1 x 107 cells were lysed in buffer A and, 
subsequently the total cellular lysates were treated with N-glycosidase F following the 
protocol by the manufacturer.  
 
2.2.3.4. DISC analysis by immunoprecipitation and Western Blot 
1 x 108 cells were treated with 1 µg/ml of anti-APO-1 antibodies at 37°C for 
indicated periods of time, washed twice in 1 x PBS and subsequently lysed in buffer 
A (stimulation condition) or lysed without treatment (unstimulated). The CD95 DISC 
was immunoprecipitated overnight with 2 µg of anti-APO-1 and 30 µl protein A 
sepharose beads. Protein A sepharose beads were washed five times with 20 
volumes of lysis buffer. The immunoprecipitates were analyzed on 8, 10 and 12 % 
PAAG. Subsequently, the gels were transferred to Hybond nitrocellulose membrane 
(Amersham Pharmacia Biotech., Germany), blocked with 5% nonfat dry milk in 
PBS/Tween (PBS plus 0.05% Tween 20) for 1 h, washed with PBS/Tween, and 
incubated with the primary antibodies in PBS/Tween at 4°C overnight. Blots were 
developed with a chemoluminescence method following the manufacturer’s protocol 
(Perkin Elmer (Jügesheim, Germany) Life Sciences, Germany).  
 
2.2.3.5. Enzyme-linked immunosorbent assay (ELISA) 
Flexible 96-well plates from BD Transduction Laboratories (Heidelberg, Germany) 
(USA) were coated with 100 µl of anti-CD95 (Abcam (Cambridge, Germany)) 
antibody in 0.05 M carbonate-bicarbonate buffer pH 9.6 (CBB) at 4°C overnight. Then 
the plates were washed 3 times with distilled water, blocked with 200 µl of PBS 
containing 3% bovine serum albumin (BSA) at RT for 2 hours, which was followed by 
washing 3 times with PBS containing 0.5% Tween 20 (PBS-T). 100 µl of total cell 
lysates were added to each well, which was followed by incubation at RT for 1 h. 
After incubation, the plates were washed 3 times with PBS-T. This was followed by 
addition of 100 µl of peroxidase-conjugated goat anti-mouse IgG antibody (Jackson 
ImmunoResearch Laboratories) diluted at 1:5000 in PBS-1% BSA. The plates were 
incubated for 1 h at 4°C. After incubation, the pla tes were washed 3 times with 
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PBS-T and then the reaction was revealed with 100 µl of OPD 0.4 mg/ml (Sigma-
Aldrich (Steinheim, Germany)) in 0.05 M phosphate-citrate buffer, pH 5.0 solution for 
10-20 min at room temperature. After stopping the reaction with 100 µl of 3N H2SO4, 
the plates were read with an ELISA reader (Wallac, Gaithersburg, USA) at 490 nm.  
 
2.2.4. Methods of molecular biology 
2.2.4.1. Preparative scale isolation of plasmid DNA 
The purification of plasmid DNA was performed with the Plasmid Maxi or Mini Kit 
(Qiagen (Hilden, Germany)). Bacteria containing the transformed plasmid were 
cultured in 300 ml LB medium containing 50 µg/ml ampicillin, overnight at 37ºC in an 
incubator (300 rpm). The next day, the bacteria were harvested by centrifugation at 
6000g for 15 min at 4ºC. After discarding the supernatant, the bacterial pellet was 
resuspended in 10 ml of the supplied buffer P1. To lyse the cells, 10 ml of buffer P2 
were added to the samples, mixed by inverting the tube 4-6 times, and incubated at 
RT for 5 min. To stop the lysis, 10 ml of chilled buffer P3 was added, mixed well, 
incubated on ice for 20 min, and then centrifuged at 13000g. The QIAGEN (HILDEN, 
GERMANY)-tip 500 columns were equilibrated by applying 10 ml of buffer QBT, and 
the column was allowed to drain by gravity. The supernatant containing the plasmid 
was filtered through a filter paper into the column and allowed to enter the column by 
gravity. The column was washed 2 times with 30 ml of buffer QC. To elute the 
plasmid DNA, 15 ml of buffer QF was applied to the column and the eluate was 
collected into a fresh tube. The DNA was precipitated by adding 0.7 volumes 
(10.5 ml) of isopropanol, followed by centrifugation at 4ºC at 13000 g for 30 min. The 
DNA pellet was washed with 5 ml of 70% ethanol and centrifuged again at 4ºC for 
15 min. After pouring off the ethanol, the pellet was dried at RT and then 
resuspended in the required amount of sterile water.  
 
2.2.4.2. Preparation of competent bacteria  
For preparation of competent bacteria, 10 ml of an overnight culture of DH-5α 
E. coli were inoculated into 300 ml LB-media and further cultured at 37°C in a shaker 
until the OD600 = 0.6. The bacterial culture was cooled down for 10 min and then 
pelleted by centrifugation at 4000 rpm at 4°C for 5  min. The supernatant was 
discarded and the pellet was resuspended in 40 ml ice-cold 100 mM CaCl2 buffer and 
incubated on ice for 10 min. This step was repeated two times. The pellet was 
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resuspended in 8 ml ice-cold 100 mM CaCl2 buffer, incubated on ice for 10 min and 
aliquoted. Aliquots of 100 µl cell suspension were stored at -80°C until usage.   
 
2.2.4.3. Transformation of plasmid DNA in competent bacteria  
Competent bacteria (100 µl) were thawn on ice and plasmid solution was gently 
mixed with the bacterial solution and incubated on ice for 30 min. After 30 min a heat 
shock was performed at 42°C for 1 min. The reaction  mix was transferred to a 
LB-agarose plate containing ampicillin (50 µg/ml). The plate was incubated overnight 
at 37°C.  
 
2.2.4.4. Restriction enzyme digestion and ligation of DNA fragments  
The plasmid DNA and DNA fragments were prepared by cutting it with suitable 
restriction enzymes for 1 h at 37 ºC in a following typical reaction: 
Cutting of DNA fragments obtained by PCR  
5 µl  DNA fragment  
1 µl  restriction enzyme  
5 µl  buffer 10x  
Add to 50 µl with H2O 
Restriction digestion of plasmid DNA  
1 µg  plasmid  
1 µl  restriction enzyme  
5 µl  buffer 10x  
Add to 50 µl with H2O 
The fragments were separated on an agarose gel and purified out of the gel. For 
ligation, 1:3 molar ratio of vector:insert DNA fragments together with 1 µl of T4 DNA 
ligase were incubated in 1 x ligation buffer in a total volume of 20 µl at 16ºC 
overnight.  
 
2.2.4.5. Measurement of DNA concentration  
The concentration of DNA was determined by measuring the absorbance at 260 nm 
using a spectrophotometer. For measuring the absorbance, the spectrophotometer 
was first calibrated with 100 µl of H2O. Then 5 µl of DNA sample was diluted with 
95 µl H2O, transferred to a quartz cuvette, and the absorbance was recorded at 260 
and 280 nm. The concentration of DNA was calculated by using the following 
formula:  
Absorbance at 260 nm (A
260
) x dilution factor x 50 µg/ml = x µg/ml 
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2.2.4.6. Site-directed mutagenesis  
To generate CD95-glycomutants site-directed mutagenesis was performed. 
Asparagine and Threonine at 118, 136, 214 and 223 amino acid positions were 
changed to Glutamine by point mutations in CD95 cDNA using PCR. Primers were 
chosen by Stratagene Primer Designer program. All procedure was done according 
to manufacturer instructions and following typical reaction: 
PCR mix  
19.2 µl  H2O 
3.0 µl  10x buffer 
0.6 µl  dNTP mix 
3.0 µl  Forward primer 
3.0 µl  Reverse primer 
0.6 µl  pKEX-APO-1 plasmid (5 ng/mkl) 
0.6 µl  PfuUltra 
Final volume 30 µl 
 
PCR program and DpnI treatment 
95°C 1 min  
95°C 50 sec  
60°C 50 sec x18 
68°C 9 min   
68°C 10 min   
37°C pause  
+ 0.6 µl DpnI  
37°C 60 min  
 
XL10-Gold cells were transformed according to manufacturer procedures with the 
ready glycomutants, plated to ampicillin agar-plates overnight. Five colonies for each 
mutant were picked up and cultured overnight in SOC media. Next morning plasmid 
was purified and presence of the mutations was analyzed by GATC sequencing 
service (GATC (Konstanz, Germany)).  
 
2.2.4.7. Isolation of total cellular RNA 
Total cellular RNA was isolated with the use of a RNeasy Protect Mini Kit l (Qiagen 
(Hilden, Germany)) reagent based method according to the manufacturer’s protocol. 
Essentially, approximately 2 x 106 cells were pelleted (1500 rpm, 10 min) and 
suspended in 1 ml TRIzol reagent. After 10 min incubation at room temperature, 
200 µl chloroform were added, the sample was mixed and further incubated for 3 min 
at room temperature. The mixture was centrifuged at 12000 rpm, at 4oC for 15 min. 
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The aqueous phase was collected and transferred to a new tube avoiding 
contamination with the protein precipitates. The RNA was precipitated by addition of 
500 µl isopropanol, incubation for 10 min at room temperature and subsequent 
centrifugation at 12000 rpm, 4oC for 15 min. After the removal of isopropanol, the 
RNA was washed with 75% EtOH, centrifuged for 10 min at 12000 rpm, 4oC, and 
dried at room temperature. RNA content was measured spectrophotometrically at a 
wavelength of 260 nm and purity was assayed by measurement of the 260/280 nm 
ratio.  
 
2.2.4.8. Semi-quantitative RT-PCR and PCR 
Total RNA was subjected to mRNA-specific RT-PCR reaction to synthesize cDNA 
(GeneAmp RNA PCR kit, Applied Biosystems, USA). The composition of the reaction 
mixture applied is listed below (volumes are given for one reaction vial). Synthesized 
cDNA was stored at -20oC. 
RT-PCR program and DpnI treatment 
95°C 5 min  
4°C 2 min  
42°C 60 min  
70°C 15 min   
 
cDNA synthesized in the RT-PCR step was used as a template for classical PCR 
reaction. The content of the reaction mixture is listed below (volumes are given for 
one reaction vial): 
PCR program 
95°C 5 min  
95°C 60 sec  
52°C 60 sec X30 
68°C 60 sec   
68°C 10 min   
4°C pause  
 
The PCR programs used are listed below. The PCR products were resolved using 
1% agarose gel containing 0.001 % EtBr.  
 
2.2.4.9. Purification of PCR products  
Purification of PCR products prior to restriction enzyme digestion was done with 
the PCR purification kit (Qiagen (Hilden, Germany)). All centrifugation steps were 
performed at 10000 g in a conventional table top micro centrifuge. 5 volumes of 
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buffer PB, which is provided by the kit, were mixed with 1 volume of the PCR sample. 
A QIAquick spin column was placed in a 2 ml collection tube. The mixture was 
applied to the QIAquick column and centrifuged for 1 min. The flow through was 
discarded. 0.75 ml wash buffer PE from the kit was added to the QIAquick column 
and centrifuged for an additional 1 min to completely remove the residual buffer. The 
QIAquick column was transferred in a clean 1.5 ml microcentrifuge tube and the DNA 
was eluted. 50 µl H2O was placed directly on the filter and left on the column for 2 
min. Then the column was centrifuged for 1 min. DNA concentration was analyzed, 
using spectrophotometry.  
 
2.2.4.10. Purification of DNA fragments from agarose gels  
To obtain the desired DNA fragments, DNA was run in agarose gel and the gel 
was cut by using a scalpel and transferred to an eppendorf (Wesseling-Berzdorf, 
Germany) tube. DNA was purified according to the QIAquick Gel Extraction kit 
(Qiagen (Hilden, Germany)). Briefly, the DNA fragment was excised from the agarose 
gel. The gel slice was transferred in a tube and 3 volumes of buffer QG were added 
to 1 volume of gel. The mixture was incubated at 50ºC with shaking for 10 min to 
dissolve the gel. When the gel was dissolved completely, one gel volume of 
isopropanol was added to the mixture. The mixture was applied to a QIAquick column 
and centrifuged for 1 min. The flow-through was discarded and the QIAquick column 
was placed back in the same collection tube. The DNA was washed with 0.75 ml of 
buffer PE and centrifuged again for 1 min. The flow-through was discarded and the 
QIAquick column was centrifuged for an additional min and the QIAquick column was 
placed into a 1.5 ml eppendorf tube. DNA was eluted by adding 50 µl buffer EB to the 
center of the membrane and centrifuged for 1 min. DNA was stored at -20ºC before 
further use.  
 
2.2.6. Bioinformatical methods 
To find possible posttranslational modifications human CD95 protein sequence of 
the full-length receptor was submitted to several prediction programs on CBS Server 
of Center for Biological Sequence Analysis www.cbs.dtu.dk/services/). For prediction 
of palmitoylation sites CSS-Palm 2 web server has been used. Generic 
phosphorylation sites in CD95 have been predicted by NetPhos 2.0 server 
(www.cbs.dtu.dk/services/NetPhos/) (Blom et al. 1999) with a threshold of 0.5 (level 
Olga Shatnyeva 
 
63 
Materials and Methods 
under which prediction considered as insignificant). Kinase specific phosphorylation 
sites have been predicted by NetPhosK 1.0 server 
(www.cbs.dtu.dk/services/NetPhosK/) (Blom et al. 2004) with a threshold of 0.5. 
C-mannosylation sites have been predicted by NetCGlyc 1.0 Server 
(www.cbs.dtu.dk/services/NetCGlyc/) (Julenius 2007) with a threshold of 0.5. 
Palmitoylation sites have been predicted by CSS-Palm 2.0 server 
(csspalm.biocuckoo.org/online.php) (Ren et al. 2008) with a threshold of 0.5. N-linked 
glycosylation sites have been predicted by NetNGlyc 1.0 server 
(www.cbs.dtu.dk/services/NetNGlyc/) with a threshold of 0.5. O-linked (GalNA) 
glycosylation sites have been predicted by NetOGlyc 3.1 server 
(www.cbs.dtu.dk/services/NetOGlyc/) (Julenius et al. 2005) with a threshold of 0.5.  
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3. RESULTS 
3.1. CD95 from Type I and Type II cells shows a different protein 
modification pattern upon Western blot analysis 
Type I cells are characterized by an increased amount of DISC formation in 
comparison to Type II cells despite similar CD95 expression levels on the cell surface 
(Fig. 6, see section 1.2.1.1.3 for details) (Scaffidi et al. 1998). A possible explanation 
for the difference in CD95 signaling in Type I and Type II cells could be that different 
posttranslational modifications or a splicing pattern of CD95 exist. To check this 
hypothesis CD95 expression levels and protein modification patterns in Type I and 
Type II cells were tested by Western blot analysis of total cellular lysates.  
 B lymphoblastoid SKW6.4, T leukemia Hut78 and B lymphoma BJAB cells were 
used as a model for Type I cells whereas Jurkat cells ( subclone J16) and CEM cells 
served as a model for Type II cells, respectively (Scaffidi et al. 1998). Detection of 
CD95 was performed by anti-CD95 polyclonal antibodies C20 after Western blot 
(Schmitz et al. 2002). This analysis revealed significant differences in CD95 protein 
patterns between selected Type I and Type II cells (Fig. 13). Two different CD95 
forms with corresponding molecular mass of 48 and 55 kDa were seen in Type I 
cells. However, only one form of the receptor with a molecular mass of approximately 
50 kDa was detected in Type II cells. 
Instead of 12% SDS-PAGE gels used in Fig. 13A 10% SDS-PAGE gels were also 
used to improve protein separation (Fig. 13B). As seen before two major bands in 
case of Type I cells (SKW6.4 and Hut78) as well as one major band in the case of 
Type II cells (JA3, J16, J27 and CEM) were observed. Thus, it has been found that 
there are different forms of CD95 receptor in Type I and Type II cells. An 
investigation of the origin for Type I/Type II CD95 signaling on the level of CD95 
could, therefore, potentially explain the underlying cause for different sensitivity of 
cells towards CD95-induced apoptosis in these two types of cells. 
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Figure 13. Different protein modification pattern of CD95 in Type I and Type II cells. A. 
CD95 protein patterns were analyzed in the total cellular lysates of SKW6.4, Hut78, BJAB 
and J16 cells on 12 % SDS-PAGE followed by Western blot with anti-CD95 polyclonal 
antibodies C20. B. CD95 protein modification patterns were analyzed in the total cellular 
lysates of SKW6.4, Hut78, J27, JA3, CEM and J16 cells on 10% SDS-PAGE followed by 
Western blot with anti-CD95 polyclonal antibodies C20. CD95 bands in Type I cells are 
indicated by black arrows, the CD95 band in Type II cells by a grey one. 
 
3.2. Analysis of alternative splicing of CD95 in Type I and Type II 
cells  
The presence of different splice variants of CD95 in Type I and Type II cells 
was investigated. Total mRNA was purified from Type I cells: BJAB, Hut78, SKW6.4 
cells, primary T cells (day 6) and from Type II cells: J16 cells, primary T cells (day 1). 
RT-PCR analyses using three pairs of primers (Cascino et al. 1995) that amplify 
three different regions of the CD95 gene were performed (Fig. 14). The combination 
of these sets of primers is sufficient to identify different splice products.  
RT-PCR analysis using primer pairs I and III revealed no differences in CD95 
mRNA patterns between Type I and Type II cells. In all cells analyzed only one PCR 
product of 330 bp for primer pair I and III, respectively, was observed. RT-PCR 
analysis performed with primer pair II revealed one major band of 350 bp for all cell 
lines and an additional product in the region of 280 bp in Hut78 cells and day 1 
primary T cells. This product was also observed in the other cell lines, but was barely 
detectable. Taken together no differences were detected between Type I and Type II 
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cells with different pairs of primers. Therefore, alternative splicing is not a reason for 
the different CD95 protein pattern in Type I and Type II cells. 
 
 
Figure 14. Analysis of alternative splicing of CD95 in Type I and Type II cell lines. A. 
Scheme of primer pairs for the analysis of possible splice variants of CD95 (adopted from 
(Cascino et al. 1995)). B. RNA was isolated from SKW6.4, Hut78, BJAB, primary T cells (day 
1), primary T cells (day 6), J16 and CEM cells, reverse transcribed and amplified using 
primers depicted in A.  
Another reason why different splicing could be ruled out was the transient 
overexpression of CD95 in HeLa and Cos1 cells transiently transfected with plasmid 
pKEX encoding the CD95 cDNA. In this case CD95 was expressed from a plasmid 
containing a complete CD95 gene without introns. Therefore, splicing could not take 
place. Nevertheless, two different forms of CD95 were observed upon Western blot 
analysis (Fig. 15). This indicates that the different bands of CD95 proteins in Type I 
and Type II cells do not result from alternative splicing. GFP was used as a control 
for transfection efficiency and as a negative control. 
It was next analyzed whether posttranslational modifications of CD95 could be the 
reason for the presence of different forms of CD95 in Type I and Type II cells. 
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Figure 15. Transiently transfected HeLa and Cos1 cells overexpressing CD95 revealed 
the presence of two different forms of CD95. Plasmid pKEX encoding CD95 (Oehm et al., 
1992) was transfected into HeLa cells as well as into Cos1 cells. Anti-CD95 Western blot 
analysis was performed to control protein expression. Anti-actin Western blot was used as a 
loading control. 
 
3.3. In silico predictions of possible posttranslational modifications 
of CD95  
Possible modifications of CD95 were investigated with prediction programs. As 
CD95 is a type I transmembrane protein the possibility for proteolytic cleavage, 
phosphorylation, palmytoilation, mannosylation and glycosylation was tested. 
To find possible posttranslational modifications, the human CD95 protein 
sequence of the full-length receptor was submitted to several prediction programs on 
the CBS Server of the Center for Biological Sequence Analysis 
(www.cbs.dtu.dk/services/). For prediction of palmitoylation sites the CSS-Palm 2 
webserver was used. 
A possible explanation for the different observed CD95 protein modification 
patterns in Type I and Type II cells different posttranslational modifications or the 
presence of different splice variants of CD95 were considered.  
CD95 was reported to be cleaved by MMP7 (Martilysin) as the first physiologically 
relevant protease that can specifically cleave CD95 (Strand et al. 2004). Cleavage of 
CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumor cells.  
Microsequencing of the positions in CD95 cleaved by MMP7 revealed two sites in 
the N-terminal extracellular domain of CD95, important for preligand assembly of 
CD95. The resulting cleavage product of CD95 is several kDa smaller than 
Olga Shatnyeva 
 
68 
Results 
noncleaved CD95. MMP7 cleavage of CD95 results in reduced CD95 surface 
expression and decreased CD95-mediated apoptosis sensitivity of tumor cells. 
Treatment of MMP7-positive HT-29 tumor cells with MMP7-antisense 
oligonucleotides led to an increase in CD95-mediated apoptosis sensitivity (Strand et 
al. 2004). 
 
Figure 16. Prediction potential arginine and lysine propeptide cleavage sites in CD95. 
The output from PropP 1.0 is graphically represented. 
The possibility of proteolitic cleavage of CD95 was predicted by ProP 1.0 Server 
(www.cbs.dtu.dk/services/ProP/) (Duckert et al. 2004) with a threshold of 0.5. Many 
potential arginine and lysine propeptide cleavage sites were found (Fig. 16). No 
proteases cleavage sites were found with the threshold equal or higher than 0.5. 
Therefore other reasons for the presence of two CD95 bands were checked. 
 
3.3.1. Generic and kinase specific phosphorylation sites 
Generic phosphorylation sites in CD95 were predicted by NetPhos 2.0 server 
(www.cbs.dtu.dk/services/NetPhos/) (Blom et al. 1999) with a threshold of 0.5. 
Results are summarized in Fig. 17. Bioinformatic analyses have shown that CD95 
has many generic phosphorylation sites, which involve phosphorylation of Thr, Tyr 
and Ser residues. 
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Figure 17. Prediction of generic phosphorylation sites in CD95. A. Sequence of human 
CD95 followed by an assignment field describing the predicted category for each residue. 
Residues having a prediction score above the threshold are indicated by 'S', 'T' or 'Y', 
respectively. B. Graphical representation of predictions with indicated scores generated by 
the server. 
 
Figure 18. Prediction of kinase specific phosphorylation sites in CD95. A. Sequence of 
CD95. B. Potential kinase specific phosphorylaion sites with thresholds more than 0.5 were 
labeled with colors depicted on the right.  
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Kinase specific phosphorylation sites were predicted by NetPhosK 1.0 server 
(www.cbs.dtu.dk/services/NetPhosK/) (Blom et al. 2004) with a threshold of 0.5. 
Results are summarized in Fig. 18. Consistent with previous reports PKC, p38, CKI 
and CKII were revealed by this prediction. Nevertheless, there are a number of 
kinases, which have not been reported to be associated with CD95 signaling. 
 
3.3.2. C-mannosylation, palmitoylation, N-linked and O-linked 
glycosylation sites 
C-mannosylation sites were predicted by NetCGlyc 1.0 Server 
(www.cbs.dtu.dk/services/NetCGlyc/) (Julenius 2007) with a threshold 0.5. Results 
are summarized in Fig. 19. There are only four mannosylation sites predicted in 
CD95. Nevertheless, the probabilities for CD95 being mannosylated at these sites 
are low as their score were below the threshold. 
 
Figure 19. Prediction of C-mannosylation sites in CD95. The output from NetCGlyc is 
graphically represented. 
Palmitoylation sites were predicted by CSS-Palm 2.0 server 
(csspalm.biocuckoo.org/online.php) (Ren et al. 2008) with a threshold of 0.5. Results 
are summarized in Fig. 20. There are many palmitoylation sites in CD95 predicted. 
Nevertheless only two of them have a high prediction score level and have a high 
probability to be palmitoylated (pos. 104 and 199). 
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Figure 20. Prediction of palmitoylation sites in CD95. Potential phosphorylation sites are 
represented with indicated scores generated by server. 
 
Figure 21. Prediction of N-linked glycosylation sites in CD95. A. Sequence of human 
CD95 followed by an assignment field describing the predicted category for each residue. 
Asn-Xaa-Ser/Thr sequons in the sequence are highlighted in blue. Asparagines predicted to 
be N-glycosylated are highlighted in red. If the residue was predicted not to be glycosylated, 
either because the score was below the threshold or because the residue was not Asn, then 
the position is not marked. Residues having a prediction score above the threshold are 
indicated by 'N’. B. Graphical representation of prediction with indicated scores generated by 
the server. 
N-linked glycosylation sites were predicted by NetNGlyc 1.0 server 
(www.cbs.dtu.dk/services/NetNGlyc/) with a threshold of 0.5. Results are 
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summarized in Fig. 21. Bioinformatic analyses have demonstrated that there are only 
three putative N-linked glycosylation sites in CD95. Two in the extracellular domain 
(Asn118 and Asn136) and one in the intracellular domain (Asn223). 
O-linked (GalNA) glycosylation sites were predicted by NetOGlyc 3.1 server 
(www.cbs.dtu.dk/services/NetOGlyc/) (Julenius et al. 2005) with a threshold of 0.5. 
Results are summarized in Fig. 22. Bioinformatic analysis demonstrated that there 
was only one O-linked glycosylation site with a high probability in CD95 (Thr214). 
 
 
Figure 22. Prediction of O-linked glycosylation sites in CD95. A. Sequence of human 
CD95 followed by an assignment field describing the predicted category for each residue. 
Residues having a prediction score above the threshold are indicated by blue 'S’ or ‘T’, 
respectively. B. Graphical representation of prediction with indicated scores generated by the 
server. 
From all modifications, provided by bioinformatics analysis, our experimental 
efforts were concentrated mostly on glycosylation of CD95, because glycosylation 
might account for the significant shifts in molecular mass observed. Phosphorylation 
was also analyzed to a minor extent. Other modifications of CD95 and their role in 
CD95 signaling will have to be analyzed in future studies. 
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3.3. Phosphorylation is not a reason for several CD95 forms 
According to the predictions CD95 has many potential phosphorylation sites. To 
analyze if the differences in the molecular mass of the two CD95 forms are due to 
phosphorylation HeLa cells stably overexpressing CD95 (HeLa-CD95 cells) were 
used. Under these conditions two bands of CD95 are detected. CD95 was 
immunoprecipitated from cellular lysates of HeLa in the presence of the phosphate 
inhibitor (sodium vanadate) using anti-APO-1 antibody. The presence of 
phosphorylated groups was analyzed by Pro-Q Diamond staining which can detect 
phosphate groups attached to tyrosine, Ser or Thr residue. It allows detection of as 
little as 50 nanograms of phosphoprotein (Fig. 23A). The efficiency of the 
immunoprecipitation was controlled by anti-CD95 Western blot (Fig. 23B).  
 
Figure 23. Analysis of CD95 phosphorylation. A. CD95 immunoprecipitated from 
HeLa-CD95 cells, HeLa-CD95 total cellular lysates and control phosphoprotein Ovalbumin 
were analyzed with Pro-Q Diamond phosphoprotein gel stain. B. The presence of CD95 in 
the samples was controlled by Western blot.  
No phosphorylation of CD95 was detected. This does not exclude that CD95 could 
be phosphorylated at low levels. It is likely that the sensitivity of this approach was 
not sufficient to detect low levels of phosphorylation. Therefore, the main modification 
of CD95 seems to be glycosylation and the study focused on this modification. 
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3.4 Treatment with N-glycosidase F resulted in different CD95 
protein modification patterns in Type I and Type II cells  
According to the prediction, the second very prominent modification of CD95 was 
glycosylation. As mentioned before, CD95 is a sialylated N-glycosylated protein 
(Peter et al., 1995) (see section 1.2.2.2.4. for details). Therefore, it was assumed that 
the different CD95 protein modification patterns in Type I and Type II cells result from 
the different degree of N-glycosylation of CD95 in these cells. Protein modification 
patterns of CD95 were analyzed upon complete N-deglycosylation with 
N-glycosidase F, which cleaves all N-glycans from a protein (Fig. 24A). Cellular 
lysates from Type I and Type II cells treated with N-glycosidase F were analyzed for 
CD95 protein modification patterns in a 10 % SDS-PAGE with subsequent Western 
blot analysis. Untreated Type I and Type II cells were used as a control. The 
treatment with N-glycosidase F resulted in a clear shift of the two major bands in 
Type I cells (SKW6.4) to a decreased molecular mass (Fig. 24C). One major band in 
Type II cells (J27 and JA3) also shifted to a decreased molecular mass (Fig. 24C). 
Interestingly, the molecular mass of deglycosylated CD95 in Type I and Type II cells 
was different. Type II cells contain only one form of CD95 which seems to be less 
glycosylated than the “higher molecular mass form” from Type I cells and higher 
glycosylated than the ”lower molecular mass form” from Type I cells. CD95 in Type I 
cells seems to have an enhanced level of N-glycosylation and subsequently 
sialylation in comparison to CD95 in Type II cells. Treatment with N-glycosidase F 
did not result in a similar CD95 pattern in Type I and Type II cells. The data show 
clearly that there is another modification in addition to glycosylation. Nevertheless, 
there are various glycosylated forms of the receptor in both cell types. These 
differences might lead to the differences in signaling. Therefore, N-glycosylation was 
addressed in more detail. Treatment with N-glycosidase F could not be used since 
this enzyme showed a high level of unspecific deglycosylation. To further analyze the 
role of glycosylation other enzymes and inhibitors of N-glycosylation were applied 
such as a Vibrio Cholerae Neuraminidase (VCN), tunicamycin and 
deoxymannojirimycin (DMM). 
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Figure 24. The analysis of deglycosylation of CD95 with N-glycosidase F. A. The 
mechanism of action of N-glycosidase F. Variable structures of glycan side chains are 
presented in grey. B. The action of N-glycosidase F on the Ribonuclease B. C. CD95 pattern 
in indicated cell lines after N-glycosidase F treatment was analyzed by Western blot analysis 
using anti-CD95 polyclonal antibodies C20. 
 
3.5. Inhibition of CD95 N-glycosylation by tunicamycin  
3.5.1. Tunicamycin treatment leads to a change in CD95 glycosylation 
pattern 
Type I cells seems to have an enhanced level of glycosylation of CD95 compared 
to Type II cells. SKW6.4 and Hut78 were used to test if a decrease of various 
glycosylation forms of CD95 might convert Type I to Type II cells. The influence of 
N-glycosylation on CD95 signaling in cells was analyzed using tunicamycin. 
Tunicamycin acts at the ER level blocking the first step of protein N-glycosylation - 
the addition of the NacGlc from Dol-P-P to the Asn of a protein.  
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Figure 25. The analysis of deglycosylation of CD95 in Type I cells with the inhibitor of 
N-glycosylation tunicamycin. SKW6.4 and Hut78 were cultured with tunicamycin for 20 
hours, followed by analysis of tunicamycin-treated vs. untreated cells. A. CD95 pattern was 
analyzed by Western blot. Anti-JNK1 Western blot was used as a loading control. CD95 
bands in non-treated cells are indicated with black arrows, while shifts of CD95 bands in 
tunicamycin-treated cells are indicated with grey arrows. B. CD95 surface expression was 
analyzed in SKW6.4 cells. 
Tunicamycin treatment for 20 hours resulted in a shift of the relative molecular 
mass of CD95 as detected by Western blot (Fig. 25A). Three bands of CD95 were 
observed in tunicamycin-treated cells. Two lower bands resulted from the 
deglycosylation shift. The upper one apparently corresponds to the fully glycosylated 
CD95, which was already expressed before tunicamycin treatment. CD95 has been 
reported to have an estimated turnover time of about 24 hours (Peter et al. 1995). 
Thus, after incubation with tunicamycin significant amounts of fully glycosylated 
CD95 were still present. Typically, using this approach more than 50% 
deglycosylation of CD95 was observed. This conclusion can be drawn based on 
comparison of the intensity of deglycosylated and glycosylated bands in the Western 
blot (Fig. 25A).  
 
3.5.2. Tunicamycin treatment does not prevent partially deglycosylated 
CD95 from being transported to the cell surface 
It has been shown before that the partially deglycosylated extracellular domain of 
CD95 is still expressed on the cell surface upon tunicamycin treatment, while the 
nonglycosylated form is retained intracellularly (Li et al. 2007). Whether the treatment 
with tunicamycin inhibits the translocation of the deglycosylated CD95 to the cell 
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surface was analyzed by cell surface staining. (Fig. 25B). There were no significant 
differences between CD95 surface expression of tunicamycin-treated and untreated 
cells. The identification of the amount of nonglycosylated CD95 was performed by 
Western blot and revealed about 10% of the total cellular content of CD95.  
 
3.5.3. CD95 DISC formation upon tunicamycin treatment  
The central event in CD95 signaling is the formation of the DISC. CD95 DISC 
formation was analyzed in untreated and tunicamycin-treated cells. SKW6.4 and 
Hut78 were treated with 4 µg/ml of tunicamycin for 20 hours. Untreated and inhibitor-
treated cells were stimulated with 500 ng/ml anti-APO-1 antibody (Trauth et al. 1989) 
for 10 minutes at 37oC to allow DISC formation (Fig. 26). The level of procaspase-8 
as well as its cleavage product p43/p41 at the DISC was similar in tunicamycin 
treated vs. untreated cells. At the same time a decrease in c-FLIP levels at the DISC 
was observed.  
 
Figure 26. The analysis of DISC formation in Type I cells upon inhibition of 
N-glycosylation with tunicamycin. The SKW6.4 and Hut78 cells were treated for 24 h with 
4 µg/ml of tunicamycin or left untreated. CD95 DISCs were analyzed after stimulation with 
500 ng/ml of anti-APO-1 antibody for indicated time points. Western blot analysis of the 
DISCs was performed with antibodies against CD95, procaspase-8 and c-FLIP. CD95 bands 
in non-treated cells are indicated with black arrows, while shifts of CD95 bands in 
tunicamycin-treated cells are indicated with grey arrows. 
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3.5.4. Tunicamycin treatment resulted in CD95-independent cell death 
Next, signaling downstream from the CD95 DISC was analyzed. The main events 
which occur downstream of the CD95 DISC are caspase-8 activation and induction 
of cell death. 
 
Figure 27. Tunicamycin treatment causes a strong cell death. A. Total cellular lysates 
were analyzed after treatment with 1 µg/ml of anti-APO-1 antibody using Western blot with 
polyclonal antibodies C20 and monoclonal antibodies C15 against procaspase-8. Anti-JNK1 
Western blot was used as a loading control. B. c-FLIP expression was analyzed by Western 
blot using monoclonal NF6 antibodies. C. Apoptotic cell death was measured with PI staining 
in SKW6.4 cells. D. Specific cell death calculated from data in C. 
The level of caspase-8 activation was analyzed by Western blot analysis and 
showed an enhanced level of caspase-8 activation upon tunicamycin treatment 
(Fig. 27A). The analysis of cell death by propidium iodide (PI) staining in SKW6.4 has 
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revealed that tunicamycin causes a strong CD95-independent cell death up to 35% 
(Fig. 27B). Upon overnight stimulation with anti-APO-1 cell death in tunicamycin-
treated cells was 20% higher than in the untreated cells and reached 95%. But the 
level of CD95 specific cell death was decreased to 20% due to high background cell 
death (Fig. 27C).  
Tunicamycin was reported to block translation. To further investigate the 
mechanism of tunicamycin-induced sensitization towards CD95-induced apoptosis 
the tunicamycin effects on protein synthesis in the system of DR-induced apoptosis 
were analyzed. C-FLIP proteins have a short turnover and are the central inhibitors 
of CD95-induced apoptosis. Their expression upon addition of tunicamycin was 
checked by Western blot. A significant decrease in the c-FLIPS levels were detected 
(Fig. 27D). This downregulation of c-FLIPS should certainly lead to enhanced 
sensitivity towards CD95-induced apoptosis as c-FLIPS protein was reported to block 
caspase-8 activation at the DISC (Scaffidi et al. 1999).  
Thus, the action of tunicamycin in addition to N-deglycosylation results in a 
number of side effects such as the inhibition of translation leading to the 
downregulation of c-FLIP proteins and unspecific cell death. Therefore, tunicamycin 
was not ideal for the functional studies of N-deglycosylation of CD95. For further 
experimental analysis the influence of partial deglycosylation on CD95 signaling were 
tested by using enzymatic approaches.  
 
3.6. Analysis of the role of CD95 sialylation in CD95 signaling using 
Vibrio Cholerae Neuraminidase (VCN)  
3.6.1. DISC formation upon VCN treatment 
CD95 is highly sialylated protein (Keppler et al. 1999). Analysis of the influence of 
sialic acid on CD95 signaling was carried out. A set of different sialidases (for more 
details see materials and methods) was tested and it was found that Vibrio Cholerae 
Neuraminidase (VCN) from  Sigma-Aldrich (Steinheim, Germany) which preferentially 
hydrolyzes a (α2-3)-linkages of sialic acid (Fig. 28A) was the best for the following 
experiments. The conditions under which effective removal of sialic acid occurred 
within the shortest period of time were found (see materials and methods for details). 
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Treatment of SKW6.4 and Hut78 cells with VCN for one hour substantially reduced 
the relative molecular mass of CD95. The shift to the lower molecular mass was 
observed for CD95 indicating removal of sialic acid.  
To test whether sialylation of CD95 plays a role in signal transduction the 
differences in CD95 signaling upon desialylation of CD95 starting with DISC 
formation were investigated. CD95 DISC formation was compared in SKW6.4 and 
Hut78 cells treated vs. untreated with VCN (Fig. 28B). The cells were first treated 
with VCN for one hour. After complete desialylation of CD95, the cells were 
stimulated with agonistic anti-APO-1 antibody and the CD95 DISC was 
immunoprecipitated and analyzed as described before. CD95 DISCs were detected 
both upon and without VCN treatment. However, lower amounts of procaspase-8a/b, 
its cleavage product p43/p41 and the cleavage product of c-FLIPL, p43-FLIPL were 
observed in comparison to the DISCs from VCN-untreated cells (Fig. 28C). The 
full-length c-FLIPL was not detected at the DISC as it was immediately processed in 
accordance with previous publications (Chang et al. 2002; Lavrik et al. 2007). 
Notably, the amount of DED-containing proteins and processed caspase-8 at the 
DISC were reduced.  
To control that the reduced DISC formation upon VCN treatment is not due to the 
decreased affinity of anti-APO-1 antibody to desialylated CD95, ELISA analysis was 
carried out using two types of anti-CD95 antibodies. The primary antibodies were 
rabbit polyclonal antibodies and interact with the C-terminus of CD95, which should 
not be glycosylated. As secondary antibodies anti-APO-1 antibodies were used 
(Fig. 28C). The binding of desialyated and sialylated CD95 to anti-APO-1 antibodies 
was shown to be similar. Thus, the reduced DISC formation is the consequence of 
VCN treatment. 
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Figure 28. DISC formation upon VCN treatment. A. The mechanism of action of VCN. 
Variable structures of glycan side chains are presented in grey. B. CD95 DISCs were 
analyzed after treatment with 1 µg/ml of anti-APO-1 antibody for indicated time points. 
Western blot analysis of the DISCs was performed with antibodies against CD95, 
procaspase-8 and c-FLIP. CD95 bands in untreated cells are indicated with black arrows, 
while shifts of CD95 bands in VCN-treated cells are indicated with grey arrows. C. ELISA 
analysis for the binding of anti-APO-1 antibody to CD95 from the lysates of untreated and 
VCN-treated SKW6.4 cells. 
3.6.2. Decreased formation of CD95n oligomers upon VCN treatment 
 CD95 is published to form SDS-stable CD95 oligomers (CD95n) upon stimulation 
with the ligand or agonistic antibodies (Feig et al. 2007). The first interesting  
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observation was the reduction molecular mass of the CD95n oligomers from 220 kDa 
to 116 kDa upon treatment with VCN in Type I SKW6.4 cells (Fig. 29). These 
differences in mobility might be a result of the decreased amount of CD95 oligomers 
or because of the different mobility on the gel due to different charge or 
conformational changes of the protein upon deglycosylation. 
 
Figure 29. The analysis of desialylation of CD95 in Type I cells with Vibrio Cholerae 
Neuraminidase (VCN). SKW6.4 cells were treated with VCN for 1 hour at 370C, followed by 
the analysis of VCN-treated vs. untreated cells. CD95n oligomers were analyzed by Western 
blot for CD95. Oligomeric structures are marked with red circles. 
Interestingly, the desialylated upper band of CD95 in Type I cells had a molecular 
mass similar to the one of CD95 in Type II cells. This suggests that one of the 
differences in CD95 modification in Type I and Type II cells could be the higher level 
of sialylation of CD95 in Type I cells.  
 
3.6.3. VCN treatment resulted in CD95-independent cell death  
Apoptotic signaling in SKW6.4 and Hut78 downstream of the DISC was analyzed. 
Untreated and VCN-treated cells were stimulated with anti-APO-1 for 10 min at 37oC. 
Total cellular lysates were analyzed by Western blot using anti-caspase-8, anti-Bid 
and anti-caspase-3 antibodies. In contrast to the DISC, in total cellular lysates more 
active caspase-8 was detected upon VCN treatment than without VCN treatment 
(Fig. 30A). Moreover, caspase-3 and Bid cleavage were significantly enhanced upon 
VCN treatment (Fig. 30B). 
Olga Shatnyeva 
 
83 
Results 
 
Figure 30. Treatment with VCN resulted in unspecific cell death. A. Total cellular lysates 
were analyzed after treatment with 1 µg/ml of anti-APO-1 antibody by Western blot for CD95 
and caspase-8. Anti-Erk1 Western blot was used as a loading control. B. Caspase-3 
processing and Bid cleavage were analyzed in untreated and VCN-treated SKW6.4 cells 
using Western blot. C. Apoptotic cell death in SKW6.4 was measured with PI staining. D. 
Specific cell death calculated from data in C. 
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To address the observed contradiction between the reduced level of procaspase-8 
processing at the DISC upon VCN treatment and the enhanced level of caspase-8 
activation in the total cellular lysates upon VCN treatment cell death was measured 
by PI staining. It was found that the VCN treatment alone resulted in significant 
increase of cell death (Fig. 30C). The mechanism of this cell death is not described 
and possibly involves desialylation of other surface receptors leading to the blockage 
of many important cellular pathways, which results in apoptosis induction. Therefore, 
the cells pretreated with VCN showed an increased level of apoptosis in a CD95-
independent way, but CD95 specific cell death was diminished (Fig. 30D). This 
provides an explanation for the increased caspase-8 activity in total cellular lysates 
(Fig. 30A) upon VCN treatment. Therefore, VCN could not be applied for functional 
studies in CD95 signaling as it causes significant CD95-independent cell death. 
 
3.7. Analysis of the role of complex and hybrid N-glycans in CD95 
signaling using Deoxymannojirimycin (DMM)  
To evaluate the effect of complex and hybrid glycans 1-deoxymannojirimycin 
(DMM) was applied. DMM inhibits the ER mannosidases and Golgi mannosidase I, 
resulting in the accumulation of high-mannose oligosaccharide structures that can not 
be further modified by the terminal addition of different carbohydrate moieties (Varki 
et al. 2009). Different concentrations of inhibitor were tested and a nontoxic 
concentration which did not influence the quality of inhibition. The optimal 
concentration for DMM was 2 mM and treatment was performed for 48 hours (data 
not shown). 
 
3.7.1. DMM treatment resulted in a different CD95 protein modification 
pattern than after tunicamycin and VCN treatments. DMM does not 
change surface expression of CD95 and had no toxic effect. 
DMM treatment in SKW6.4 cells was performed for 48 hours with a daily medium 
change. Total cell lysates were analyzed by Western blot in order to check whether 
DMM altered the glycosylation patterns of CD95. The reduction in relative mass of 
CD95 corresponded to approximately 5-6 kDa for DMM-treated cells compared to 
untreated cells (Fig. 31A). Different CD95 protein modification patterns were 
observed upon DMM treatment in comparison to tunicamycin and VCN treated cells. 
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Three bands of CD95 were observed in DMM-treated cells. Two lower bands 
apparently result from a shift of deglycosylation. The third upper one probably 
corresponds to glycosylated CD95.  
 
 
Figure 31. Analysis of deglycosylation of CD95 in SKW6.4 cells with the inhibitor of 
N-glycosylation, DMM. SKW6.4 cells were cultured with DMM for 48 h, followed by the 
analysis of DMM-treated vs. untreated cells. A. The CD95 pattern was analyzed by Western 
blot analysis using anti-CD95 polyclonal antibodies C20. CD95 bands in untreated cells are 
indicated with black arrows, while shifts of CD95 bands in DMM-treated cells are indicated 
with grey arrows. B. CD95 surface expression was analyzed in SKW6.4 cells. C. Apoptotic 
cell death in SKW6.4 cells was measured with propidium iodide staining.  
Cell surface expression of the N-glycosylated proteins treated with DMM should 
not be influenced because they undergo proper folding in the ER. Therefore the 
amount of CD95 on the cell surface in untreated and DMM-treated SKW6.4 cells was 
analyzed. No differences were found between treated and untreated cells (Fig. 31B). 
Thus, DMM treatment does not regulate CD95 apoptotic signaling via cell surface 
expression. 
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To analyze sensitivity to CD95 induced apoptosis in DMM-treated cells cell death 
was determined by PI-staining upon incubation with different amounts of antagonistic 
anti-APO-1 antibody (Fig. 31C). DMM treatment modulated the sensitivity to CD95 
induced apoptosis at low anti-APO-1 concentrations. The level of cell death was the 
same upon stimulation with high anti-APO-1 concentrations. 
 
3.7.2. CD95 DISC formation upon DMM treatment 
To analyze the influence of DMM on CD95 DISC formation DISC levels were 
compared in untreated and DMM-treated SKW6.4 cells (Fig. 32).  
 
Figure 32. DISC formation upon DMM treatment is reduced. CD95 DISCs were analyzed 
after treatment with 500 ng/ml of anti-APO-1 antibody for 15 min. Western blot analysis of the 
DISCs was performed with antibodies against CD95, procaspase-8 and FADD. Anti-IgG 
Western blot was used as a loading control for the immunoprecipitation. CD95 bands in 
non-treated cells are indicated with black arrows, while CD95 bands in DMM-treated cells are 
indicated with grey arrows. 
As a control for the diminished CD95 DISC formation SKW6.4 cells treated with 
tunicamycin as described above were used. The cells were treated with DMM for 48 
hours which resulted in a complete inhibition of formation of the CD95 complex and 
hybrid glycans. After 48 hours cells were stimulated with agonistic anti-APO-1 
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antibodies and the CD95 DISC was immunoprecipitated and analyzed. The levels of 
active caspase-8 and FADD at the DISC were marginally decreased upon DMM 
treatment compared to untreated cells and higher than in tunicamycin-treated cells 
(Fig. 32). This observation suggests that complex and hybrid glycans are important 
for the proper CD95 DISC formation and apoptotic signaling of CD95. 
 
3.8. Investigation of the role of CD95 glycosylation by site-directed 
mutagenesis  
3.8.1. Single aminoacid substitutions as a specific approach to generate 
CD95 glycosylation mutants 
Analysis of glycosylation patterns of the receptor using enzymatic and inhibitory 
approaches was informative, but it was not applicable for functional analysis due to 
the unspecific deglycosylation of many cellular proteins that resulted in a high degree 
of CD95-independent cell death. To specifically study CD95 glycosylation sites-
deficient glycosylation mutants were generated by site-directed mutagenesis. 
Asparagine and threonine residues were changed for glutamine in order to not 
significantly change the local structure and charge of CD95. Single and double 
mutants in different combinations were used (Fig. 33A).  
HeLa cells were used to study CD95 glycosylation mutants. In all cases, the 
impact of N-glycosylation on CD95 function was assessed by surface staining, DISC 
formation and cell death analysis after transient transfection or in cell lines stably 
expressing CD95 WT or corresponding glycosylation mutants.  
 
3.8.2. Construction of single and double glycosylation mutants of CD95 
As discussed above, CD95 has three potential N-glycosylation sites (Asn118, 
Asn136 and Asn223) and one O-glycosylation site (Thr214) (Fig. 33A). 
Accordingly, the CD95 single mutations were named CD95 (N118Q,) CD95 
(N136Q), CD95 (T214Q) and CD95 (N223Q) and CD95 (N118Q/N136Q), CD95 
(N118Q/T214Q), CD95 (N118Q/N223Q), CD95 (N136Q/T214Q) and CD95 
(N136Q/N223Q) for the double mutants, respectively.  
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Figure 33. Generation of CD95 glycosylation mutants. Scheme of all created 
glycosylation mutants for CD95.  
 
3.8.3. Analysis of CD95 glycosylation mutants in HeLa cells 
3.8.3.1. Expression of WT and mutant CD95 in HeLa cells 
CD95 glycosylation mutants were expressed in HeLa cells upon transient 
transfection (Fig. 34A) and detected by Western blot. Upon expression of wild-type 
CD95 (WT) two bands were detected. 
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Figure 34. Expression of CD95 glycosylation mutants upon transient transfection. A. 
Expession of CD95 glycosylation mutants in HeLa cells. The pattern of CD95 was analyzed 
by Western blot analysis using anti-CD95 polyclonal antibodies C20. CD95 (WT) bands are 
indicated with black arrows, while CD95 bands from glycosylation mutants are indicated with 
grey arrows. B. CD95 pattern in HeLa cells transfected with CD95 (WT) and CD95 
glycosylation mutants after N-Glycosidase F treatment was analyzed by Western blot 
analysis using anti-CD95 polyclonal antibodies C20.  
In case of expression of glycosylation mutants deficient on one of the extracellular 
glycosylation sites three CD95 bands were observed. All of them correspond to the 
differentially glycosylated CD95. 
No differences in CD95 protein modification pattern for the CD95 (T214Q/N223Q) 
mutant were found in comparison with WT CD95. This shows the absence of 
intracellular glycosylation of CD95. The most remarkable difference in CD95 protein 
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modification pattern was observed in the case of CD95 (N118Q/N136Q) mutant, 
where an additional lower band was observed. This band likely corresponds to the 
nonglycosylated CD95.  
 
3.8.3.2. Analysis of CD95 glycosylation mutants using N-glycosidase F  
To check that the CD95 protein modification pattern in case of the CD95 
(N118Q/N136Q) double mutant corresponds to those of completely deglycosylated 
CD95, lysates from cells transiently expressing glycosylation mutants were treated 
with N-glycosidase F. As expected, all mutants except  the CD95 (N118Q/N136Q) 
double mutant which lacks both extracellular glycosylation sites demonstrated a shift 
of CD95 protein modification pattern upon treatment with this enzyme (Fig. 34B). 
Only in case of CD95 (N118Q/N136Q) the protein modification pattern was not 
changed. This result suggests that this mutant does not contain any N-glycans. 
Nevertheless, even in the case of CD95 (N118Q/N136Q) a double band in CD95 
protein modification pattern was still observed.  
 
3.8.3.3. Comparison of cell surface expression and DISC formation in HeLa 
cells transiently transfected with glycosylation mutants  
First, cell surface expression and DISC formation of CD95 glycosylation mutants 
were checked. Transiently transfected with the same amounts of the CD95 
constructs HeLa cells were analyzed 36 hours after transfection. Cell surface 
expression was analyzed by surface staining with anti-APO-1 antibody by FACS. The 
ability to form a DISC after triggering of the receptor was tested under conditions 
described above (Fig. 35A). 
CD95 surface staining has demonstrated that all the mutant proteins are 
translocated to the cell surface (Fig. 35A). These results suggest that the protein 
folding of the mutants occur normally and glycosylation mutants are not retained in 
the ER. Moreover, no significant differences in DISC formation were observed 
(Fig. 35B).  
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Figure 35. Cell surface expression and DISC formation in HeLa cells transiently 
transfected with CD95 glycosylation mutants. A. Cell surface staining of WT CD95 and 
CD95 glycosylation mutants for transiently transfected HeLa cells was performed with anti-
APO-1 IgG3 antibodies (red line). As isotype control FII23 IgG3 antibodies were used (Black 
and violet lines). To control efficiency of CD95 surface expression  the HeLa-CD95 stable cell 
line was used (green line) (Neumann et al., in press). B. The CD95 DISC was analyzed after 
treatment with 500 ng/ml of anti-APO-1 antibody for 15 min. Western blot analysis of the 
DISCs was performed with antibodies against CD95, procaspase-8, FADD. CD95 bands of 
CD95 (WT) are indicated with black arrows, while bands of CD95 glycosylation mutants are 
indicated with grey arrows. 
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To overcome variations of CD95 expression upon transient transfection and study 
CD95 glycosylation mutants under more physiological conditions HeLa cell lines 
stably expressing different CD95 glycosylation mutants were created and cell lines 
with similar expression levels of CD95 mutants were selected. 
 
3.8.4. Analysis of CD95 glycosylation in cell lines stably expressing CD95 
glycosylation mutants 
3.8.4.1. Generation and characterization of cell lines stably expressing CD95 
glycosylation mutants  
To generate HeLa-CD95 cell lines stably expressing different glycosylation 
mutants, HeLa cells were transfected with 200 ng of a pIRES-CD95 construct 
(Neumann et al., in press), a coding for a WT or mutants of the CD95 gene. Cells 
with a stable integration of a CD95 cassette were selected upon puromycin 
treatment. 
Cell lines expressing CD95 (N118Q), CD95 (N223Q) and CD95 (T214Q) single 
glycosylation mutants were generated. CD95 (N136Q) single and CD95 
(N118Q/N136Q) double glycosylation mutants did not survive puromycin selection. 
 
3.8.4.2. CD95 (WT) and glycosylation mutants protein modification patterns are 
the same in transiently transfected and stably expressing cells 
To check the CD95 expression levels in the produced cell lines stably expressing 
CD95 (WT) and glycosylation mutants the CD95 protein modification patterns from 
these cells were analyzed as described above. The same CD95 (WT) and 
glycosylation mutant protein modification patterns were found for transiently 
transfected HeLa cells expressing the same CD95 constructs. Moreover, for the 
single mutants deficient in intracellular glycosylation sites (N223Q and T214Q) no 
differences were found in comparison to WT receptor, where only two forms of CD95 
were detected. For the extracellular glycosylation site mutant CD95 (N118Q) three 
forms of CD95- two of those with relatively lower molecular mass- were detected 
(Fig. 36A). These findings are in good agreement with the results obtained from 
transiently transfected HeLa cells. 
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Figure 36. Production of cell lines stably expressing CD95 WT and glycosylation 
mutants. A. CD95 protein modification pattern in cell lines stably expressing CD95 
glycomutants was analyzed by Western blot analysis using anti-CD95 polyclonal antibodies 
C20. WT CD95 bands are indicated with black arrows, while CD95 bands from glycosylation 
mutants are indicated with grey arrows. B. Cell surface staining of CD95 (WT) and CD95 
glycosylation mutants in stable cell lines was performed with anti-APO-1 IgG3 antibodies. As 
isotype control FII23 IgG3 antibodies were used. 
 
3.8.4.3. Cell surface localization of CD95 (WT) and glycosylation mutants in 
HeLa stably expressing cell lines 
For the functional studies of the CD95 signaling the cell surface expression of the 
receptor plays a critical role. To select cell lines with a similar expression efficiency of 
CD95 (WT) and glycosylation mutants more than 120 cell lines, which include pools 
and single clones, were analyzed for the levels of CD95 total protein and cell surface 
expression by Western blot and flow cytometry, respectively (data not shown). On the 
basis of these analysis HeLa stably transfected cell lines which express the same 
amount of CD95 at the cell surface and contain equal amount of CD95 in total cell 
lysates were selected (Fig. 36B). 
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3.8.4.4. CD95 WT and glycosylation mutants have a similar localization within 
the cell 
To compare the localization of CD95 WT and glycosylation mutants in stably 
transfected HeLa cells immunoflourecence staining and confocal microscopy analysis 
of these cells were performed. All membrane proteins undergo a glycosylation 
procedure in order to be transported to the membrane (Parodi 2000). To check the 
possibility that abrogation of CD95 glycosylation leads to accumulation of the protein  
in the ER co-stainings for the ER marker calreticulin and the Golgi marker GM130 
were performed. No differences in the distribution of CD95 WT and glycosylation 
mutants within HeLa stably transfected cell were found (Fig. R37). 
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Figure 37. CD95 WT and glycosylation mutants distribution within the cell by confocal 
microscopy.  HeLa, HeLa stably transfected with WT CD95 and CD95 glycosylation mutants 
were plated on glass slides, fixed, stained with anti-APO-1 antibody for CD95, with 
anti-calreticulin as a specific marker for ER and with anti-GM130 as a specific marker for 
Golgi antibodies. Localization of CD95 was visualized by Alexa594-coupled secondary 
antibodies and localization of GM130 and calreticulin was visualized by Alexa488-coupled 
antibodies. Nuclei were stained with DAPI. Representative fluorescence micrographs are 
shown.  
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3.8.4.6. CD95 glycosylation mutants have the same affinity to anti-APO-1 
antibody as CD95 WT 
All previous data show that HeLa cells stably transfected with CD95 mutants 
express CD95 on the cell surface. Therefore, these mutants are an excellent tool to 
analyze the role of glycosylation in CD95 signaling. This gave a basis to analyze the 
CD95 signaling events upon anti-APO-1 treatment. However, it remained unclear, 
whether the absence of glycans induces changes in CD95 conformation, which, in 
turn, causes differences in the binding affinity of the agonistic anti-APO-1 antibody. 
To analyze this possibility binding of the anti-APO-1 antibody to CD95 (WT) and 
glycosylation mutants was measured by ELISA analysis as was described above 
(Fig. 38).  
 
Figure 38. Binding of CD95 WT and glycosylation mutants to anti-APO-1 antibody. 
Cellular lysates from HeLa cells stably transfected with CD95 WT and glycosylation mutants 
were used for anti-APO-1 specific ELISA analysis. Anti-APO-1 was used at concentrations of 
0.1, 0.2, 0.4, 0.8 and 1 µg/ml.  
We determined that CD95 (WT) and glycosylation mutants were bound to the anti-
APO-1 antibody with a similar efficiency at different concentrations of anti-APO-1. 
Thus, HeLa cells stably transfected with glycosylation mutants could be used to 
analyze DISC formation and cell death sensitivity. 
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3.8.4.7. Analysis of CD95-induced death in stable cell lines overexpressing 
CD95 glycosylation mutants  
To analyze the influence of glycosylation on CD95-induced of cell death HeLa cells 
stably transfected with CD95 (WT) or glycosylation mutants were treated with 
500 ng/ml of anti-APO-1 for 24 and 48 hours. To control specificity of the induced cell 
death another cell death inducer staurosporine was used as a positive control. Cell 
death was analyzed by PI-staining. All cell lines showed a similar level of cell death 
upon treatment with staurosporine (Fig. 39A). However, upon anti-APO-1 treatment a 
slightly higher level of CD95-induced cell death was detected in HeLa cells 
expressing CD95 (WT) in comparison with HeLa cells expressing CD95 glycosylation 
mutants (Fig. 39B). 
 
3.8.4.8. DISC formation  
To check if the observed differences in CD95-induced cell death are due to 
diminished CD95 signaling, DISC formation at the different time points was 
investigated for HeLa cell lines stably transfected with CD95 WT and glycosylation 
mutants. Three time points 10, 30 and 60 minutes were checked. Untransfected 
HeLa cells which contain endogenous CD95 were used as a control for DISC 
formation. The amount of the endogenous CD95 is at least ten times smaller than in 
HeLa cell line stably transfected with CD95 (WT) (Neumann et al., in press).  
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Figure 39. CD95-induced cell death in HeLa cells stably transfected with CD95 (WT) 
and glycosylation mutants. Apoptotic cell death was measured with propidium iodide 
staining in control untransfected HeLa cells and HeLa cells stably transfected with CD95 
(WT) and glycosylation mutants. A. Cells were treated with staurosporin to induce intrinsic 
apoptosis as a control for CD95-induced cell death. B. Cells were treated with 500 ng/ml of 
anti-APO-1 antibody to induce CD95-specific apoptosis.  
It was found that in HeLa cells stably transfected with CD95 (N118Q) glycomutant 
the amount of the CD95 DISCs formed at the latest time points are similar to those of 
CD95 (WT) and other glycosylation mutants (Fig, 40). However, the kinetic of 
procaspase-8 activation appeared slower in case of the CD95 (N118Q) glycomutant 
(Fig, 40, Lysates panel). Thus, slower kinetics of caspase-8 activation were observed 
at the DISC formed with glycosylation mutants. 
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Figure 40. DISC formation. CD95 DISCs were analyzed after treatment with 500 ng/ml of 
anti-APO-1 antibody for the indicated time points. Western blot analyses were performed with 
antibodies against CD95, procaspase-8 and FADD. CD95 bands in HeLa cells stably 
transfected with WT and glycomutated CD95 are indicated with black arrows, while 
glycomutated CD95 bands are indicated with grey arrows. 
Taken together, the experimental results demonstrate that CD95 glycosylation plays 
a role in CD95 signaling by influencing DISC formation and CD95-induced cell death. 
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4. DISCUSSION 
4.1. Possible reasons for the presence of different forms of CD95 
 Signaling of CD95 is one of the best-studied apoptotic signaling pathways. A lot of 
studies were performed to understand main CD95 mediated events such as DISC 
formation, procaspase-8 activation and signaling in Type I and Type II cells (Schmitz 
et al. 1999). CD95 exists as 45 and 55 kDa forms recognized by C20 antibodies in 
Type I cells and as one form in Type II cells (Fig. 13). The nature of these forms is 
poorly understood but all of them are capable of forming the DISC. There are two 
possible reasons for the presence of different receptor forms – alternative splicing 
and posttranslational modifications.  
  
4.2. Alternative splicing of CD95 is not the reason for the presence 
of two CD95 forms 
It was shown that alternative splicing does not contribute to the presence of 
several CD95 protein forms in the investigated cell lines. RT-PCR analysis of mRNA 
purified from these cell lines revealed the same PCR products in the case of all 
primer combinations used (Fig. 15). Additional evidence against alternative splicing 
was that transient overexpression of CD95 in HeLa and Cos1 cells resulted in the 
presence of two CD95 bands. Since CD95 was expressed from a plasmid containing 
a complete gene without introns, alternative splicing can be ruled out. Therefore, only 
posttranlational modifications of CD95 could explain the presence of two different 
CD95 bands. 
 
4.3. Analysis of possible modifications of CD95: proteolytic 
cleavage, phosphorylation, mannosylation, palmitoylation and 
glycosylation 
The possibility of CD95 proteolysis which might result in the second lower band in 
Type I cells also was not excluded. The presence of a Type I specfic protease might 
explain the second 45 kDa band. CD95 was published to be cleaved by MMP7 
(Strand et al. 2004). MMP7 is produced by the tumour cells themselves at early 
stages of tumour development. Treatment of MMP7-positive tumour cells with MMP7-
antisense oligonucleotides led to an increase in CD95-mediated apoptosis sensitivity 
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(Strand et al. 2004). Processing of CD95 by MMP7 results in a smaller differences in 
molecular mass of the CD95 than the two forms observed in Type I cells. Therefore, 
the proteolytic cleavage by MMP7 was excluded as a reason for the two forms of 
CD95 in Type I cells.  
The possibility of CD95 proteolitic cleavage was analyzed and many potential sites 
for different proteases were found. Nevertheless, no proteases were found to cleave 
CD95 with the threshold of equal or higher 0.5 (Fig. 14). Hence, proteolytic cleavage 
of CD95 was not addressed in more detail. Therefore other reasons for two CD95 
bands were checked.  
 Detailed understanding of phosphorylation of CD95 is missing. CD95 is reported 
to be phosphorylated intracellulary and extracellulary (Lautrette et al. 2006; Eberle et 
al. 2007) (Fig. 17 and 18). The potential intracellular phosphorylation sites located 
predominantly in the DD of CD95 and might influence apoptotic signaling via 
modulation of the binding of adaptor proteins. One of the potential extracellular 
phosphorylation sites is located in PLAD. Therefore, phosphorylation of this site may 
directly modulate CD95L-independent oligomerisation of CD95 and apoptosis 
signaling by blocking pre-association of the receptors. Two others are located in the 
ligand-binding region. Phosphorylation at this area might modulate CD95L binding to 
the receptor. CD95 phosphorylation was analyzed before in our laboratory by means 
of phospho-specific antibodies. CD95 phosphorylation was not detected by this 
approach (T. Mock, Diploma thesis). The method of analysis used is very sensitive to 
a number of conditions including the quality of phospho-specific antibodies. However, 
it leads not always to a proper detection of phosphorylated residues in proteins. To 
exclude phosphorylation as the reason for different CD95 forms Pro-Q Diamond 
staining was applied to analyze CD95 phosphorylation in HeLa cells in which 
overexpression of two forms of the receptor had been detected. Pro-Q Diamond 
staining is highly specific and can detect phosphate groups at the scale of several 
nanogramms of phosphorylated protein (Schabacker et al. 2006). Analysis with the 
Pro-Q Diamond staining proved that phosphorylation was not the reason for the 
presence of several forms of CD95. This allowed us to concentrate further on other 
types of posttranslational modifications – mannosylation, palmitoylation and 
glycosylation.  
Bioinformatics analysis revealed no potential C-mannosylation sites with a 
probability score higher then 0.5 (Fig. 19). Several potential palmitoylation (Fig. 20) 
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and N- and O-glycosylation sites were predicted (Fig. 21 and 22). Recent studies 
revealed that CD95 is a palmitoylated protein and that CD95 palmitoylation facilitates 
induction of apoptosis. Formation of CD95 SDS-stable aggregates has been shown 
to be regulated by palmitoylation of CD95 at cysteine 199 and was suggested to be 
important for caspase-8 activation (Feig et al. 2007). However, palmitoylation of 
CD95 does not result in large differences in relative molecular mass, as mutants of 
the palmitoylated site did not have an altered mobility in SDS-PAGE (Feig et al. 
2007). These results rules out palmitoylation as the reason for two forms of CD95. 
Taken together, mannosylation and palmytoilation could be excluded. Therefore our 
main focus was on glycosylation, since this modification might potentially lead to the 
largest difference in molecular mass of the modified proteins.  
 
4.4. Glycosylation of CD95 is important for DISC formation and 
procaspase-8 activation  
Several methods to obtain the deglycosylated receptor including enzymatic 
deglycosylation and inhibition of CD95 glycosylation and the generation of CD95 
mutants on glycosylation sites were used in the present work to study the contribution 
of glycans to the presence of different forms of CD95 as well as to CD95 signaling in 
Type I and Type II cells. 
Therefore, we analyzed CD95 patterns in Type I and Type II cells with 
N-glycosidase F. This enzyme cleaves all N-glycans from the protein. All cell lines 
contain highly glycosylated CD95. Upon treatment with the N-glycosidase F two 
forms of CD95 were detected in Type I cells. Our results suggest, that another 
modification is responsible for the presence of different forms of the receptor in 
Type I cells. Due to  the high level of deglycosylation of many cellular receptors and 
unspecific cell death N-glycosidase F could not be applied for the cell culture 
experiments. Thus, to study the role of N-glycosylation in cell culture another 
approach based on inhibition of N-glycosylation was used. Tunicamycin inhibits 
N-glycosylation completely. Upon treatment with tunicamycin, an increased CD95-
independent cell death was observed. Moreover, DISC formation could not be 
compared in untreated and tunicamycin-treated cells since tunicamycin treatment led 
to inhibition of translation. This resulted in downregulation of c-FLIP expression. 
c-FLIP is the central inhibitor of procaspase-8 activation at the DISC. Low expression 
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of c-FLIP resulted in an increased level of procaspase-8 activation and, therefore, in 
an increased level of CD95-induced apoptosis (Krueger et al. 2001; Krueger et al. 
2001; Krammer et al. 2007). Thus, tunicamycin could not be applied for our functional 
studies in vitro. 
 Until recently, only few studies addressed the role of N-glycosylation of CD95 in 
the context of sensitivity and resistance to induction of apoptosis. The high sialylation 
level of CD95 in different cell lines was suggested to be a factor defining resistance 
(Peter et al. 1995; Keppler et al. 1999). To address this question in detail partial 
deglycosylation was performed using Vibrio Cholerae neuraminidase (VCN) in 
SKW6.4 and Hut78 cells. Recombinant VCN enzyme preferentially hydrolyzes α(2-3)-
linkages of sialic acid from the glycans. VCN treatment was shown to lead to reduced 
procaspase-8 activation at the DISC. Thus, sialic acids in the CD95 glycans might 
play an important role in proper DISC formation and procaspase-8 activation. 
However, signaling downstream from the DISC using VCN could not be analyzed 
because treatment of cells with this enzyme resulted in a high level of CD95-
independent unspecific cell death, which could result from desialylation of many of 
the surface receptors.  
Application of an inhibitor of glycosylation, DMM, was an alternative to analyze the 
influence of N-glycosylation and in particular, the role of complex and hybrid 
N-glycans on CD95 function. This inhibitor does not block high mannose N-glycans 
formation. The presence of high mannose N-glycans is sufficient for proper folding of 
proteins and therefore does not induce ER stress. No toxic effects of DMM were 
observed on the cells. This observation suggests that complex and hybrid glycans on 
CD95 are needed for proper DISC formation and fine CD95 apoptotic signaling. 
Analysis of glycosylation patterns of the receptor using enzymatic and inhibitory 
approaches was not applicable due to the unspecific deglycosylation of many cellular 
proteins that resulted in a high degree of CD95-independent cell death. To 
specifically study CD95 glycosylation site-deficient glycosylation mutants were 
generated by site-directed mutagenesis.  
All methods together showed that deglycosylation of CD95 did not significantly 
impair CD95 DISC formation but diminished procaspase-8 activation. These effects 
were detectable only upon stimulation with low concentrations of CD95 antagonists. 
Under these so-called threshold conditions the amount of CD95 DISCs is low and the 
amount of caspase-8 just high enough to trigger apoptosis (Bentele et al. 2004; 
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Lavrik et al. 2007). Therefore, the decrease of caspase-8 caused by deglycosylation 
of CD95 might result in a blockage of apoptosis.  
Inhibitors of glycosylation with an exception of tunicamycin as well as glycosylation 
mutants demonstrated a decrease of procaspase-8 activation at the DISC. A 
reduction of CD95-induced apoptosis was observed upon treatment with DMM, 
tunicamycin and VCN. In contrast to tunicamycin and VCN, DMM did not possess 
any toxicity towards the cells tested. Upon DMM treatment combined with CD95 
stimulation cell death was mediated by deglycosylated CD95. In contrast, treatment 
with VCN and tunicamycin was toxic to the cells and the effects on cell death 
mediated by deglycosylated CD95 were difficult to consider independently from 
toxicity. 
Recently, it was reported that O-glycosylation of TRAILR1 (DR4) and TRAILR2 
(DR5) plays a central role in sensitivity and resistance regulation towards TRAIL- 
induced apoptosis (Wagner et al. 2007). Only one predicted O-glycosylation T214 
site was found for CD95. T214 was not glycosylated and did not play any role in 
CD95 function (Fig. 41). CD95 glycomutant T214Q as well as N223Q showed the 
same CD95 protein pattern upon SDS-PAGE analysis and no influence on DISC 
formation and CD95-mediated cell death. Furthermore, N-glycosylation of CD95 does 
not have a strong effect in the regulation of CD95-induced apoptosis. These results 
show that CD95 is not modified at the potential intracellular glycosylation sites T214 
and N223. The CD95 extracellular glycosylation sites N118 and N136 were 
addressed in more detail. 
Analysis of cell death showed a different kinetics upon anti-APO-1 stimulation. 
This revealed that cells with mutation CD95 (N118Q) showed slower kinetics of 
caspase-8 activation compared to cells with CD95 (WT). Moreover, this phenomenon 
was specific for cells expressing the CD95 (N118Q) mutant. A control experiments 
with staurosporine, which induces intrinsic apoptosis, showed an equal level of cell 
death in all cell lines. Formation of the DISC upon anti-APO-1 stimulation was 
diminished in the case of cells expressing the CD95 (N118Q) mutant compared to 
cells expressing CD95 (WT) receptors and intracellular glycosylation sites mutants. 
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Figure 41. Predicted N- and O-glycosylation sites in all members of the death 
receptors family. Results of N-glycosylation and O-glycosylation sites in death receptors 
were predicted by NetNGlyc 1.0 and NetOGlyc 3.1 servers, respectively. Cysteine-rich 
domains are in green, transmembrane domains are in light blue, death domains are in red. 
The CARD-like domain at the C-terminus of DR6 was found by bioinformatic analysis and is 
depicted in yellow. Potential N-glycosylation and O-glycosylation sites are shown as 
schematic orange and pink oligosaccharides above and below the protein, respectively.  
 
4.5. Only one glycosylation site of CD95 is conservative between 
species 
Analysis of the alignment of 16 sequences of CD95 from different species 
indicates that the N residue of the first N-glycosylation site, which corresponds to 
N118 in human CD95, is the most conserved one, while the second and third 
N-glycosylation sites, which correspond to N136 and N223 in human CD95, are less 
conserved (Fig. 42).  
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Figure 42. Alignment of CD95 sequences from different organisms. ClustalX2 sequence 
alignment of CD95 ECD across different species. Sequence abbreviations: Homo sapiens 
(HUMAN); Macaca fascicularis (MACFA); Macaca nemestrina (MACNE); Cercocebus 
torquatus (CERTO); Macaca mulatta (MACMU); Macaca arctoides (MACAR); Macaca 
assamensis (MACAS); Aotus trivirgatus (AOTTR); Callithrix jacchus (CALJA); Oryctolagus 
cuniculus (RABIT); Sus scrofa (PIG); Ovis aries (SHEEP); Felis catus (FELCA); Bos taurus 
(BOVIN); Mus musculus (MOUSE) and Rattus norvegicus (RAT). Sequences from NCBI 
Protein databank. Color lines on the top of the alignment indicate Cysteine residues forming 
disulphide bonds in human CD95. Asn-Xaa-Ser/Thr sequons are indicated by red boxes.  
Moreover, Asn-Xaa-Ser/Thr sequon in case of the second N-glycosylation site 
N136 is less conserved. Only in three organisms from all that were analyzed the 
probability of N136 residue to be potentially glycosylated is given (Fig. 43). 
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Figure 43. Prediction of glycosylation potentials for two extracellular CD95 
glycosylation sites. Probability of glycosylation (glycosylation potential) of sequons at 
positions 118 and 136 in human CD95 and their analogues in CD95 from other species was 
calculated by NetNGlyc 1.0 server.  
 
4.6. In silico modelling of CD95 DISC core structure and network 
showed that both glycosylation sites might play and important role 
in CD95 signaling 
 The possible explanation for the role of CD95 glycans in initial CD95 DISC 
formation and later on in the formation of a complex CD95 DISC network on the 
membranes could be obtained from 3D modeling of the CD95 system (Shatnyeva et 
al. Manuscript in preparation and Kubarenko et al. Unpublished data and personal 
communication). 
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Figure 44. Formation of the human CD95 DISC core structure. A. Formation of a CD95-
CD95L trimer upon binding of CD95 ECDs to the CD95L ECDs. B. Close look on the 
interface between CD95 and CD95L ECDs. Glycan attached to the N118 of CD95 is far away 
from CD95L ECD. C. Glycan attached to the N136 of CD95 is in a close proximity to CD95L 
ECD and could form extensive hydrogen bonds (green dotted lines) with the residues 200-
204 of CD95L. In all cases: light blue - CD95 ECD (ectodomain); orange - glycan, attached to 
CD95 ECD; grey - CD95 TM (transmembrane domain); green - CD95 DD (death domain); 
light pink - CD95L ECD; light yellow - glycans, attached to CD95L ECD; membrane is 
depicted in light grey. Pictures were adopted with kind permission from Dr. A. Kubarenko 
(Shatnyeva et al. Manuscript in preparation).  
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 The presence of a CD95L trimeric complex  might lead to the formation of the 
CD95 DISC core structure. This structure is composed of three molecules of CD95 
and three CD95L (Fig. 44A). Upon formation of this CD95 DISC core structure, a 
glycan moiety attached to N136 of CD95 could be important for complex formation 
and/or stability a it is located in close proximity to one of the CD95L molecules 
(Fig. 44B). It could form extensive hydrogen bonds with residues 200-204 of CD95L 
(Fig. 44C). At the same time, a glycan attached to the N118 residue of CD95 is most 
probably not important for the formation and/or stability of CD95 DISC core structure. 
It is located more distal from the CD95-CD95L interface (Fig. 44B).  
 
Figure 45. Structure of the closed and open forms of human CD95 DD. A. CD95 DD in 
closed (inactive) conformation in the free receptor. B. CD95 DD in an open (active) 
conformation in the CD95-CD95L complex. Pictures were adopted with kind permission from 
Dr. A. Kubarenko (unpublished data and personal communication).  
CD95 DISC core structure formation leads to interaction of DD on the other side of 
the membrane of corresponding CD95 molecules (Fig. 44A). This interaction results 
in the stabilization of the “open” (active) conformation of DD (Fig. 44В and 45B) 
capable to interact with FADD as it was proposed by Scott et al. 2009(Scott et al. 
2009). Moreover, in the intracellular core structure of CD95 DISC formed by three 
“open” CD95 DDs (Fig. 44A) exposed extended helices of death domains could 
interact with similar helices of the death domains of other CD95 DISC core 
structures. Assembly of CD95-CD95L trimers results in the formation of a branched 
2D CD95 network on the membrane with six CD95 DISC complexes forming one 
network (Fig. 46).  
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Figure 46. Formation of a potential human CD95 DISC network. Structure of six CD95-
CD95L complexes on a membrane forming the basic element of a CD95 DISC network. Light 
blue - CD95 ECD (ectodomain); orange - glycan, attached to CD95 ECD; grey - CD95 TM 
(transmembrane domain); green - CD95 DD (death domain); light pink - CD95L ECD; light 
yellow - glycans, attached to CD95L ECD; dark yellow - FADD DED (death effector 
domains); membrane is in the sticks representation in light grey. Pictures were adopted with  
kind permission from Dr. A. Kubarenko (unpublished data and personal communication). 
The model of the CD95 DISC interaction network is in an agreement with the 
formation of single ring-like structures upon CD95 DD - FADD DD. As it could be 
seen from the model of CD95 DISC interaction in the network glycans attached to 
N118 distant from CD95-CD95L interface in the single DISC core complex could be 
important for the interactions between two DISCs (Fig. 47). 
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Figure 47. Extracellular and intracellular interactions upon formation of the CD95 DISC 
network. A. View of the basic elements of the CD95 DISCs network from the extracellular 
space where CD95 and CD95L ECDs are located. B. View of the basic elements of the 
CD95 DISCs network from the intracellular space where CD95 DD and FADD are located. 
Distance between centers of DISCs approximately 90 Å. In all cases: light blue - CD95 ECD 
(ectodomain); orange - glycand, attached to CD95 ECD; grey - CD95 TM (transmembrane 
domain); green - CD95 DD (death domain); light pink - CD95L ECD; light yellow - glycans, 
attached to CD95L ECD; dark yellow - FADD DED (death effector domain); membrane is in 
the sticks representation in light grey. Pictures were adopted with kind permission from 
Dr. A. Kubarenko (unpublished data and personal communication). C. Formation of DISC-like 
structures and proposed mechanism of CD95 network formation adopted from (Scott et al. 
2009). 
Open cavities and interacting extended helices of two CD95 DDs from neighboring 
CD95 DISC core complexes provide the binding region for the two FADD molecules 
(Fig. 48).  
While formation of the CD95 DISCs network is initiated by interaction of open 
CD95 DD of different CD95 DISC core structures inside the cell, the glycan attached 
to the residue of CD95 ECD could be important for the stabilization of the DISC-DISC 
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interaction. Removal of this glycan upon mutation of N118 to Q could lead to 
decreased stability of the CD95 DISC network and as a result less stable binding of 
procaspase-8 to its binding site at the CD95 DD - FADD interface and to less rapid 
caspase-8 activation.  
 
Figure 48. Composition and interactions in the CD95 DISC. Figure: light blue - CD95 
ECD (ectodomain); orange - glycans, attached to CD95 ECD; grey - CD95 TM 
(transmembrane domain); green - CD95 DD (death domain); light pink - CD95L ECD; light 
yellow - glycans, attached to CD95L ECD; dark yellow - FADD DED (death effector 
domains); pink – schematic representation of procaspase-8. Pictures were adopted with kind 
permission from Dr. A. Kubarenko (Shatnyeva et al. Manuscript in preparation). 
Our findings provide evidence that the CD95 glycostructure can contribute to DISC 
formation and a potential DISC network and, thus, to the threshold of apoptotic 
signaling defining cell death initiation. This regulation might be important for cancer 
cells when a subtle difference in the amount of activated caspase-8 regulates life or 
death of the cell (Lavrik et al. 2007). Further insight into the organisation of CD95 and 
the DISC in the future will also come from sophisticated direct microscopy 
observation. 
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